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ABSTRACT
Carnitine acetyltransferase (CAT) catalyzes the reversible transfer of 
short chain (less th an  six carbons in length) acyl groups between carnitine 
and coenzyme A (CoA). This reaction likely modulates the reserves of free 
CoA and acetyl-CoA in  each organelle and membrane in  ways specific to the 
local demands. To probe the structures of the molecular interactions between 
carnitine and the active site in CAT, we have designed and synthesized 
conformationally constrained reaction-interm ediate analogues, which not 
only inhibit enzymatic activity, bu t also help reveal the topography of the 
active site.
The syntheses of (2R,6R )-, (2S,6S )-, (2R,6S)-, and (2S,6R)-6 - 
carboxylatomethyl-2-hydroxymethyl-2,4,4-trimethylmorpholinium are
described. The single-crystal X-ray structures of these compounds are 
presented. These four stereoisomers are tested as specific inhibitors of CAT. 
The results confirm the hypothesis th a t there is two-point recognition by CAT 
for carnitine and acetyl-CoA is the th ird  locus for chiral recognition. The 
results also strongly support the proposed mechanism for acetyl transfer 
between carnitine and CoA.
The syntheses of methyl (2S,6S;2R,6R)- and (2S,6R;2R,6S)-2-[6-(2- 
cyanoethyl)-4,6-dimethylmorpholinyl]acetate and the resolution of 5-(N,N- 
dimethylamino)-4-hydroxy-4-methylpentanenitrile are also described.
x
C h a p t e r  I
INTRODUCTION
1.1. G E N E R A L
C arnitine (3-hydroxy-4-trimethylammoniobutanoate, see below), a 
n a tu ra l constituent of higher organisms, is absolutely necessary for efficient
CU  p u
(CHl)3K  2- C O -  R = H; carnitine.
RO H R = acyl; acylcarnitine.
metabolism of long-chain fatty  acids . 1 " 5  F atty  acids are activated by forming 
acyl-coenzyme A (acyl-CoA) on the outer mitochondrial m em brane, whereas 
they are oxidized in  the mitochondrial m atrix. Long-chain acyl-CoA 
molecules cannot penetrate the inner mitochondrial m em brane leading into 
the m atrix. Acyl groups m ust be transferred  to carnitine to form 
acylcarnitine, which can penetrate the membrane. Once inside the matrix, 
the acyl groups are transferred  back to coenzyme A (CoA) and oxidation can 
then  occur. The oxidation of fatty  acids occurs also in peroxisomes . 3 >4 >6 >7  The 
oxidation in peroxisomes is not complete, bu t term inates a t acyl-CoA residues
of short- and medium-chain length . 3  These chain-shortened acyl-CoA 
residues are then  esterified to carnitine and the resulting acylcarnitines are 
transported out of peroxisomes for further metabolism. A recent study 8  
suggests th a t carnitine is involved in  the metabolism of both short- and long- 
chain acyl-CoAs w ithin lymphocytes and phagocytes. Carnitine may play a 
significant role in  the metabolism of medium-chain fatty  acids as well . 9  In 
addition, carnitine can buffer the acylation state of the CoA pool in  ways 
specific to the local metabolic dem ands . 1 9
C arnitine is essential for good health. Tissues with inadequate 
concentrations of carnitine exhibit severely im paired cellular energy 
m etabolism . 1  A diverse collection of diseases are related to carn itine . 1 -5  
Since the discovery of the first case of hum an carnitine deficiency , 1 1  carnitine 
has been used for therapy . 1 2  Alzheimer's disease is the most common cause 
of dem entia in  developed countries and affects about 3-4 million 
Am ericans . 1 3  The progression of Alzheimer's disease can be significantly 
reduced by adm inistration of acetylcarnitine . 1 3  Carnitine also plays an 
essential role in  hum an nu trition . 5 - 1 4  Requirem ent for carnitine is increased 
by rapid growth (infancy, or the repletion of protein-calorie undernutrition), 
pregnancy, lactation, metabolic acidosis, certain drugs excreted in  acidic 
form, renal dialysis and renal tubu lar disorders . 1 4
Carnitine functions as an acyl carrier in  fatty  acid metabolism and 
acts as a buffer for the acyl-CoA/CoA ratio. The reversible acyl transfer 
between carnitine and CoA is catalyzed by carnitine acyltransferases
3CoAS-
acyltransferase q
N - M e  / v
M e M e
O
N—M e
M e M e
CoASH
carnitine
Schem e 1.1
coenzyme A
(Scheme 1.1 ) . 2 "4 ’ 1 5  Therefore, both carnitine and  carnitine acyltransferases 
play vital roles in  fatty  acid metabolism and are essential for good health. 
Carnitine acetyltransferase (CAT), carnitine octanoyltransferase (COT), and 
carnitine palm itoyltransferase (CPT) have been identified. They are 
classified on the basis of their subcellular localization and substrate 
specificity . 2  CAT, which is selective for short-chain acyl groups, is found in 
mitochondria, peroxisomes, and microsomes . 1 6  COT w ith specificity for 
medium-chain/long-chain acyl groups is found in  peroxisomes and 
microsomes . 1 ^ ' 2 1  CPT, selective for long-chain acyl groups, is found on the 
mitochondrial outer m em brane (CPT-I) and in  the mitochondrial m atrix 
(CPT-II).17>18>22-27 CPT is also found in  microsomes , 2 8  peroxisomes , 2 9 ’3 0  
erythrocyte plasm a m em brane , 3 1  and sarcoplasmic reticulum . 3 2  
Considerable overlap of acyl chain length selectivity occurs for COT and CPT. 
Our long-range goal is to elucidate the structures of the molecular 
interactions between carnitine and the active sites on these enzymes. 
Identifying these molecular interactions will lead to a better understanding 
of the physiological chem istry and, more specifically, of the regulation of the 
enzymes. This project will focus on CAT.
1.2. CARNITINE ACETYLTRANSFERASE
CAT is widely distributed in  nature, occurring in different organisms 
from yeast to m am m als . 2  Very high CAT activities are observed in  ra t  heart, 
testis, and brown adipose tissue . 3 3  CAT is also uniformly distributed in the 
nervous system . 3 4 -3 5
CAT has been purified from different tissues and organelles, including 
pigeon breast muscle hom ogenate , 3 6 ' 3 0  pig h ea rt , 4 0  mouse liver 
peroxisomes , 2 0  yeast peroxisomes , 4 1  yeast m itochondria , 4 1  yeast cell-free 
extract , 4 2 -4 3  r a t  liver m itochondria , 4 4 -4 5  r a t  liver peroxisomes , 4 6  r a t  liver 
microsomes , 4 6  ra t  liver homogenate , 4 5  bovine h ea rt,31,41 bovine 
sperm atozoa , 4 7  chick embryo liver , 3 0  and hum an liver . 4 8  In  general, CATs 
from different sources have sim ilar properties w ith molecular weight ranging 
from 51,000 to 75,000 and pH optimum between 7.2 and 8.0 . 1 6  Most of the 
CATs show the highest activities w ith C3  or C4  acyl groups . 1 6
The wide distribution of CAT indicates its im portant physiological 
functions. The role of CAT in  buffering acetyl-CoA/CoA ratio in the 
m itochondrial m atrix  has been established . 1 0  In  the mitochondrial m atrix, 
free CoA is required for the function of the citric acid cycle, for p-oXidation, 
for the detoxification of organic acids, for the oxidative degradation of amino 
acids, and as a substrate  for pyruvate dehydrogenase and a-ketoglutarate 
dehydrogenase. Therefore, lack of free CoA can lim it the mitochondrial 
capacity for energy production. CAT can m odulate the acyl-CoA pools and 
facilitate formation of free CoA under conditions of accum ulating acyl-CoA.
In hum an muscle tissue, an  increase in  acetylcarnitine occurs during 
endurance exercise , 4 9 *5 0  indicating th a t, under the regulation of CAT, 
carnitine functions as an  acceptor for an  acetyl group to buffer excess acetyl- 
CoA formed from pyruvate decarboxylation and P-oxidation and release CoA 
for energy production. The modulation of the acyl-CoA pools may also be 
im portant in  metabolic regulation in  normal tissue , 2  protecting the tissue 
from build-up of toxic acyl-CoA5 1 - 5 3  and providing a pathw ay for storing or 
excreting the acyl moieties if  th e ir  norm al m etabolism  is im p aired . 2 -5 3 -5 4  
Acetylcarnitine can serve as a reservoir of activated acetyl units and provide 
an  im m ediate source of energy . 2 - 1 0  CAT found in  endoplasmic reticulum  and 
in  peroxisomes can convert cytosolic acetylcarnitine into acetyl-CoA, which 
could be used for the synthesis of malonyl-CoA in  the heart. Accumulation of 
acetyl-CoA in  the cytoplasm would also serve to decrease the free CoA 
available for fatty  acid activation . 5 5  CAT in  each organelle or m em brane can 
m odulate the reserves of free CoA and acetyl-CoA in  ways specific to the local 
dem ands . 1 0  The buffer role of CAT in  general fits in  well w ith the tissue 
distribution of the enzyme, which correlates w ith high metabolic activity . 5 6 -5 7  
Another im portant role for CAT is th a t i t  may shuttle short-chain 
acylcarnitines out of peroxisomes for tissues th a t chain-shorten long-chain 
fatty  acids via peroxisomal P-oxidation . 2 - 1 0
The functions of CAT indicate its im portant roles in  hum an health. 
The significance of CAT in  hum an health  was dem onstrated by the 
discoveries th a t deficiency in  CAT activity was present in  the brain  and other
tissues of a patien t suffering from fatal ataxic encephalopathy 5 8  and in  the 
brain, heart, and kidney of a  baby w ith poor respiration, failure to thrive and 
low levels of esterified carnitine in  u rin e . 5 9  CAT activity is decreased in  the 
brains and microvessels of patien ts w ith Alzheimer's disease . 6 0
A large litera tu re  exists about CAT. The advances in  the area of CAT 
up to 1987, including physical properties, kinetics, and inhibition of CAT, 
have been reviewed by Colucci and G andour . 1 6  Several generalizations have 
been m ade about the CAT-catalyzed acetyl transfer reaction between 
carnitine and CoA. The binding of carnitine and acetylcarnitine probably 
requires recognition of both carboxylate and quaternary  ammonium portions 
of the molecule and m ay involve recognition of charge. Binding of carnitine 
occurs by an  induced-fit m echanism  and binding of CoA, or acetyl-CoA, 
occurs in  a lock-and-key fashion. The kinetic m echanism fits a random -order 
equilibrium  model. The molecular m echanism  of acetyl transfer is probably 
addition-elim ination w ith general base catalysis of hydroxy attack on a 
thioester in  the forward reaction and general acid catalysis of oxygen 
expulsion in  the reverse.
This section will sum m arize recent progress in  the area of CAT 
enzymology.
1.2.1. CATs from different species
Table 1.1 lists three CATs purified from different species in  recent 
years. The molecular weights of these enzymes are sim ilar to other CATs . 1 6
The results of the study of Bloisi et al4 8  indicate th a t hum an liver CAT is a 
monomer, sim ilar to mouse liver CAT . 2 0  The pH optimum for activty of CATs 
from chick embryo liver and yeast S. cerevisiae are sim ilar to most of the 
others, while the pH optimum for activity of CAT from hum an liver is higher 
th an  others . 1 6  U nder pH 6.0, the enzyme from S. cerevisiae undergoes an 
irreversible inactivation. The substrate specificity of the enzyme from chick 
embryo liver is sim ilar to th a t  of CAT in  pigeon breast muscle w ith maximum 
activity w ith acetyl group, bu t different from most of the others th a t utilize 
C3  or C4  acyl group as the optimal substra te . 1 6  The CAT from hum an liver 
has the highest activities w ith C3  acyl groups, which is sim ilar to most of the 
other CATs . 1 6
Table 1.1. CATs purified  from different species
Enzyme
source
M olecular
w eight
pH
optim um
Isoelectric
point
Ref.
H um an liver 60,500 8.7 6.3 48
Chick embryo liver 64,000 8 . 0 30
Y east S. cerevisiae 65,000 7.5-8.0 43
Table 1.2 lists the apparen t K m values of CATs for different chain- 
lengths of substrates in  the forward and reverse reactions. The K m values 
indicate th a t these enzymes bind CoA (or acetyl-CoA) more tightly th an  they 
bind carnitine (or acetylcarnitine). For the CATs from chick embryo liver 
and hum an liver, the K m values for carnitine also indicate th a t short-chain
acyl-CoAs are preferential substrates when the concentration of carnitine is 
low.
Table 1.2. V alues of K m of CATs for different substra tes
Enzyme
source
S ubstra te
K m (|iM)
Ref
acyl-CoA carn itine CoA acylcarnitine
H um an c 2 21.3 97 420 48
liver c 3 28.0 86 650
c 4 53.5 152
C6 54.9 120
C8 50.3 148 1390
Cio 64.0 580
Chick c 2 52 160 86 800 30
embryo C4 130 250 53 890
liver C6 66 1100 78 900
C8 94 2000 66 670
S. cerevisiae C2 17.7 170 43
1.2.2. Amino acid sequences of CATs
A cDNA encoding for inner mitochondrial CAT of yeast S. cerevisiae 
was isolated by screening a yeast cDNA X gtll library  w ith antibody . 6 1  The 
whole coding sequence, which consists of 670 amino acid residues w ith a 
molecular weight of 77.3 kDa, was obtained from the cDNA and from a YEP 
13 DNA clone identified using the cDNA as probe. The identity  of this 
isolated cDNA was confirmed by using it  to d isrupt the yeast chromosomal 
CAT gene. The elim ination of CAT activity from the mitochondria of the
transform ed cells was shown by m easuring CAT activity and by immunoblot. 
The acetylcarnitine content of these cells decreased significantly, indicating 
th a t no other major CAT activity rem ained in  the cells. The residual low 
CAT activity in  the cytosol of m u tan t cells did not change, suggesting th a t 
this cDNA codes for the m itochondrial isoenzyme of CAT.
The gene YAT13 2  from S. cerevisiae encodes a protein of 6 8 8  amino 
acids with a calculated molecular m ass of 77.9 kDa, which displays 
significant sequence sim ilarity to vertebrate carnitine acyltransferases and 
yeast inner mitochondrial CAT. The researchers of th is  study failed to prove, 
by m utan t phenotype analysis, the exact substrate  specificity of the encoded 
enzyme. Based on other evidences and  data, they suggest th a t th is novel 
gene is likely to code for a m inor mitochondrial outer CAT.
1.2.3. Inhibition of CATs
For a detailed review of inhibition of CAT up to 1987, see ref. 16.
I.2.3.I. CoA analogues
Table 1.3 lists three CoA analogues th a t inhib it CATs from different 
sources.
Vessey et al6 3  have studied the effect of carboxylic acid xenobiotics and 
their m etabolites on the activity of carnitine acyltransferases and found th a t  
benzoyl-CoA and salicylyl-CoA are potent inhibitors of CAT. For the forward 
reaction, both benzoyl-CoA and salicylyl-CoA are competitive inhibitors
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Table 1.3. CoA analogues
Name Structure Enzym e source Ref.
O
benzoy 1-CoA ^ C o A  Sigma, St. Louis, M O , USA 63
salicy ly 1-Co A CoA Sigina, St. Louis, M O , USA 63
etomoxiryl-CoA
O
CoA  
(CH2)— O Cl
purified rat liver peroxisomes 64
purified nit heart mitochondria 64
partially purified rat liver mitochondria 64 
pigeon breast muscle (commercial) 64
versus acetyl-CoA with K\ values of 2 2  and  7.5 gM respectively. For the 
reverse reaction, both are competitive inhibitors versus CoA with K\ values of 
17 and 9.5 |_iM respectively. For comparison, they determ ined the K\ for end- 
product inhibition by CoA and obtained the value of 22 |iM. Benzoyl-CoA has 
about the same K\ as CoA. Salicylyl-CoA has a lower K\ for the enzyme than  
CoA or benzoyl-CoA. The results indicate th a t benzoate group has little 
effect on binding. It is not clear why the addition of a hydroxy group should 
improve the interaction w ith the enzyme.
Etomoxiryl-CoA is another CoA analogue inhibitor th a t was tested 
w ith CATs from different sources . 6 4  The da ta  are sum m arized in  Table 1.4. 
The concentrations of etomoxiryl-CoA required for 50% inhibition of the 
different CATs are in  the low micromolar range.
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Table 1.4. Inhibition of CATs by etomoxiryl-CoA
Enzyme source Kj (pM) Comment
Purified from rat liver peroxisomes 2 Mixed-type inhibition with acetyl-CoA
Purified from rat heart mitochondria 9 Mixed-type inhibition with acetyl-CoA
Partially purified from rat liver mitochondria 2 Mixed-type inhibition with acetyl-CoA
pigeon breast muscle (commercial) 3 Uncompetitive inhibition with acetyl-CoA
I.2.3.2. Carnitine analogues
Studies of carnitine analogues w ith CAT have detailed the criteria for 
molecular recognition a t its active site . 1 6  Table 1.5 lists several carnitine 
analogues th a t have been synthesized and assayed recently . 6 5 -6 6  HDH, Ac- 
HDH, (f?!S)-3-amino-5,5-dimethylhexanoic acid, and (i?S)-A^-acetyl-3-amino- 
5,5-dimethylhexanoic acid are competitive inhibitors of pigeon breast CAT. 
(f?)-(+)-HDH, (<S)-(-)-HDH, CR)-3-amino-5,5-dimethylhexanoic acid, and (S)-3- 
amino-5,5-dimethylhexanoic acid are stereoselective competitive inhibitors of 
CAT. None of them  is a substrate for CAT. These results indicate th a t the 
positive quaternary  ammonium charge on carnitine is essential for CAT 
catalysis.
In  order to determ ine the active conformation about C2-C3 of 
carnitine, Brouillette et al6 7  designed cyclic carnitine analogues which 
contain defined spatial relationships between the quaternary  ammonium, 
hydroxy, and carboxylate moieties (table 1.6). None of them  is a  substrate
12
T ab le  1.5. Inhibition of CAT by carnitine analogues
Name Structure Value ((J.M) Enzym e source Ref.
(±  )-3-Hydroxy-5,5-dim ethyl- 
hexanoic acid (HDH)
C H 3 OH
8,300 Pigeon breast 65
(±}-3-A cetoxy-5,5-dim ethyl- 
hexanoic acid (Ac-HDH)
C H 3 G A c
C O ,
4,100  Pigeon breast 65
(/?)-(+)-3-Hydroxy-5,5-dimethyl- 
hexanoic acid (HDH)
C H 3 OH
C O ,
20,300 Pigeon breast 65
(,S')-(-)-3-Hydroxy-5,5-dimethyl- 
hexanoic acid (HDH)
C H , OH
7,500  Pigeon breast 65
(/6S')-3-Amino-5,5-dimethyI 
hexanoic acid
C H 3 NH
2,600 Pigeon breast
(/6S’)-N-Aeetyl-3-am ino-5,5- 
dim ethylhexanoic acid
C H 3 N H A c
C O , 24,800 Pigeon breast 66
(,S')-3-Amino-5,5-dimethyl 
hexanoic acid
C H , NH
1,900 Pigeon breast 66
(ft)-3-Aminc>-5,5-dimethyl 
hexanoic acid
C H 3 N H 2
,C O , 9,200 Pigeon breast 66
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for pigeon breast CAT a t concentrations up to 10 mM. They are weak 
competitive inhibitors of CAT. The K\ values are much larger th an  the K m 
for CR)-carnitine (300 pM) or (R)-acetylcarnitine (300 pM). The results reveal 
th a t these analogues bind much less tightly than  carnitine or acetylcarnitine 
to CAT. The possible reasons 6 7  for the results are th a t (1) none of the 
conformations of the analogues represents the bound conformation for 
carnitine or acetylcarnitine, or (2 ) the extra steric bulk provided by the 
cyclohexyl ring residues interferes w ith binding.
Table 1.6. Inhibition of CAT by rigid carnitine analogues 
C om pound (racemate) R (p M )
H 4 ,100
A c 3 ,700
H 2 ,900
A c 10,700
H 15,900
A c 23 ,000
NMe.
OR
NMe-
OR
H
NMe.
OR
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I.2.3.3. B ile acids
Bile acids have different inhibitory effects on CAT (Table I.7 ) . 6 8 -6 9  
While determ ining the concentration of carnitine in  ra t  bile, Sekas and 
P au l 6 8  have observed th a t the concentration increased progressively as the 
bile was diluted, which prompted them  to study inhibition of bile acids on
Table 1.7. Bile acids as inh ib ito rs of CAT
Nam e Struct ure E nzym e source Ref.
cholic acid
HO
C O O H
OH
purified pigeon breast m uscle 68
deoxycholic acid
HO
C O O H
purified pigeon breast m uscle 68
lithocholic acid
C O O H
H O ....
purified pigeon breast m uscle 68
chenodeoxy cholic 
acid
C O O H
HO'"" OH
purified pigeon breast m uscle 68
rat liver peroxosom es (in vitro) 69
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CAT. They have examined inhibitory effects of major bile acids found in  bile. 
All bile acids tested (Table 1.7) inhibit CAT to varying degrees. At 
physiological concentrations, the degree of inhibition is chenodeoxycholic > 
cholic > deoxycholic > lithocholic acid. For the forward reaction, K j value for 
chenodeoxycholic acid is 520 pM. The inhibition is competitive with 
carnitine. The reverse reaction is inhibited by 25, 30, 63, and 89% in the 
presence of 0.23, 0.45, 0.90, and 1.6 mM chenodeoxycholic acid, respectively. 
They have also studied inhibition of CAT by bile acids in  ra t  liver 
peroxisomes . 6 9  The apparent K\ value is 890 pM. Inhibition is observed both 
in  vitro and ex vivo.
I.2.3.4. Conform ationally constrained reaction-interm ediate  
analogues
This type of inhibitors is the most powerful tool in  probing the 
structure of enzyme binding sites while they are in  the conformations 
adopted for catalysis. Several of this type of inhibitors have been synthesized 
and tested . 1 6  Table 1.8 lists three analogues th a t have been tested 
recently . 7 0  Table 1.9 lists their inhibition constants with various CATs. All 
these hem iacylcarnitinium s are competitive inhibitors. HAC binds better 
than  CR)-carnitine, (R)-acetylcarnitine, or CoA to CAT. HBC weakly inhibits 
CATs. It binds to CATs less tightly than  do the substrates. The degree of 
inhibition is HAC > HPrC > HBC due to the different substitution groups on 
C2 (methyl, ethyl, and phenyl group). Nonracemic HAC inhibits CAT more
16
strongly th an  racemic HAC , ? 1  indicating the im portance of configurations of 
C2  and C6  in enzyme recognition.
Table 1.8. Conformationally constrained reaction-interm ediate analogues
Name Structure
(2S,<5ft)-6-(Carboxylatomethyl)-
2-hydroxy-2,4,4-trimethyl-
morpholinium
(hemiacetylcarnitinium, HAC)
H OH
CH
-O
Me Me
(2S,6/?)-6-(Carboxylatomethyl)- 
2-ethyl-2-hydroxy-4,4- 
dimethylmorpholinium 
(hemipropanoylcarnitinium, HPrC)
H OH
N
Me' Me
(2S,h/?)-6-(Carboxylatomethyl)- 
2-hydroxy-4,4-dimethyl-2- 
phenylmorpholinium 
(hemibenzoylcarnitinium, HBC)
H OH
Ph
M e Me
The inhibitory activity of HAC is explained by its structural sim ilarity 
to the tetrahedral-in term ediate proposed in  the acetyl transfer between CoA 
and acetylcarnitine (Figure I . l ) . 7 1 >7 2
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Table 1.9. Inhibition constants of hem iacylcarnitinium s w ith CAT
Enzyme source Substrate Am(pM) Inhibitor Ai(|xM)
Rat liver peroxisomes (R )-Acetylcarnitine 290 + 20 HAC 69 ± 5
(-R)-Carnitine 143
Rat heart mitochondria CoA 130 ±20 92 ± 14
Pigeon breast (R)-Carnitine 1 2 0 HPrC 200 ±30
(i?)-Acetylcarnitine 350
Pigeon breast (-R)-Carnitine 1 2 0 HBC 3500 ± 500
Rat heart mitochondria CoA 1 2 0  ± 1 0 2400 ± 70
Rat liver peroxisomes (Rl-Acetylcarnitine 280 ± 10 1670 ± 70
C oA
O.
M e
M e
CH
M e  M e
F igu re 1.1. S tru c tu ra l re la tionsh ip  betw een th e  
proposed te trah ed ra l-in te rm ed ia te  in  the  acetyl 
tra n sfe r reaction and  the  s tru c tu re  of HAC
I.2.3.5. Other inhibitors
Methylglyoxal bis(guanylhydrazone) (MGBG) inhibits purified pigeon 
b reast CAT w ith K\ value of 1.6 mM . 7 3  I t is competitive w ith CR)-carnitine. 
The competitive inhibition of MGBG w ith  carn itine  is probably due to the 
s tru c tu ra l s im ilarity  betw een MGBG and  carn itine  or acetylcarnitine as 
proposed by Brady et a l . 7 3  The guanidium  group occupies the quaternary
ammonium site and the chain extends in  a sim ilar fashion to carnitine with 
an imine group occupying a  position sim ilar to the acyl carbonyl. In this 
location, MGBG can form a thioam inal with either CoA or cysteine present in 
the active site.
1.2.4. Summary
Some ideas are fu rther confirmed. CAT enzymatic catalysis requires a 
positive quaternary  ammonium charge on carnitine. The chiralities of 
(acetyl)carnitine and the proposed tetrahedral-interm ediate are im portant 
for CAT catalysis.
3 ^ ^ N “ N H “ Ct
NH
CH
C n h 2
NH
n h 2
MGBG
H um an liver CAT4® and chick embryo liver CAT®  ^ are inhibited by 
Ca2+ which doesn't inhibit other avian and m am m alian CATs. 1 6
Mouse liver CAT is inhibited by alachlor, a herbicide . 7 4
^CCH9C1
Ns.
c h 2o c h 3
alachlor
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1.3. DESIGN OF INHIBITORS OF CARNITINE 
ACYLTRANSFERASE
The carn itine acy ltransferases are  a fam ily of enzym es th a t  differ 
w ith respect to subcellu lar location, su b stra te  specificity, and  sensitiv ity  
to in h ib ito rs . 2  They catalyze acyl tra n sfe r  betw een carn itine  and  CoA 
(Scheme 1.2). The th ree-d im ensional s tru c tu res  of these  pro te ins are 
unknow n.
= J)H
S - M e  / '
M e M e
+ CoAS— p— R 
O
A cyltransferase  q  
 ►
O 4 \ +
*  N —M e / \
M e M e
carnitine
+  CoASH
coenzym e A
Schem e 1.2
In  order to probe the  s tru c tu res  of the  m olecular in teractions 
betw een carn itine  and  the active sites in  these enzymes, we have designed 
conform ationally constrained  analogues to mimic the  proposed reaction- 
in term ed iate  for acyl tra n sfe r  betw een carn itine  and  CoA. By com paring 
inhib ition  constants (ATj's) of a series of conform ationally constrained 
analogues, we can identify  the  topographical a rran g em en t of the key 
recognition sites on these  enzymes.
1.3.1. C onsiderations in  the enzym e in h ib itor  d esign
Several considerations m ust be m ade w hen designing 
conform ationally constrained  reaction-in term ediate  analogue inhibitors.
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F irs t, we m ust consider the possible enzyme recognition sites in  the 
substra tes. The enzym es, especially CAT , 7 5  recognize trim ethyl- 
am m onium , carboxylate, and  acyl group on acylcarnitine. Recent 
stud ies 6 5 - 6 6  suggest th a t  the  positive q u a te rn ary  am m onium  charge on 
carn itine is essen tia l for CAT catalysis. The enzymes also recognize CoA.
Second, the  conform ations of the substra te s  m ust be considered. 
There are  n ine possible conform ations for carn itine . To design a 
conform ationally constrained  analogue, we need to know which of the 
nine conform ations of carn itine  is bound to the enzyme. The 
conform ational analyses of carn itine and  acety lcarn itine have been 
perform ed by using  single crystal X-ray diffraction , 7 2  NMR, and 
m olecular m echanics (MM2 ) . 7 6  Those s tru c tu ra l s tud ies 7 2 - 7 6  show th a t 
carn itine  and  acety lcarn itine strongly prefer gauche (-) conform ation 
about N-C4-C3-0 torsion angle.
Based on these  conform ational analyses of carn itine  and 
acety lcarn itine, we can lock the  N-C4-C3-0 torsion angle in  the  gauche (-) 
conform ation by form ation of a ring  and  probably no t lose m uch in  
binding to th e  enzyme. These analogues m ust have groups necessary  for 
enzyme recognition anchored to the  conform ationally constrained 
m olecular fram ew ork in  a  w ell-defined stereochem istry.
Third, the  enzyme inh ib ito rs should mimic the  s tru c tu re  of a 
reaction-in term ediate  or a tran sitio n  s ta te  of the  m echanism . 
W olfenden 7 7  has pioneered the  developm ent of tran sitio n -s ta te  analogue
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inh ib ito rs of enzymes. The idea is th a t  enzymes bind tran sitio n  
s tru c tu res  or reaction-in term ediates more tigh tly  th an  reac tan ts  or 
products. Molecules th a t  resem ble the  s tru c tu res  of tran sitio n  s ta tes  or 
reaction-in term ediates, b u t are  unreactive, will b ind strongly to the 
enzymes. A m echanism  for acetyl tran sfe r in  CAT has been proposed 7 2  
(Scheme 1.3) based on chem ical model stud ies of O-to-S acyl tra n s fe r . 7 8  I t  
is presum ed th a t  a  sim ilar m echanism  operates in  COT and CPT . 7 9
c o a s  ;
N - M e  \/
M e M e
O.
'N - M e
\
Me7 M e
tetrahedral intermediate
CoAS
/  \
M e M e
Schem e 1.3
In  form ing such a  te trah ed ra l-in te rm ed ia te , the  th io la te  should 
approach th e  acyloxy from the  less-congested side (carboxylate on 
carn itine  "folded" back). This a ttack  arrow  is on the Re face of the ester, 
p resum ing th a t  the acyloxyl group is in  the  m ost stab le conform ation . 7 6  
This R  configuration of the  te trah ed ra l-in te rm ed ia te  can adopt a
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conform ation th a t  favors in tram olecu lar e lectrostatic  catalysis.80 The 
developing negative charge on the carbonyl oxygen would be stab ilized  by 
the  positively charged trim ethylam m onium  group. The enzym es also 
recognize the  configuration a t  C3 of (acyl)carnitine du rin g  the  acyl 
transfer. A reaction-in term ediate  analogue m u st mimic both  of these 
configurations.
1.3.2. D esign  o f reaction -in term ed iate  an alogu es
Conform ationally constrained  analogues are  the m ost effective for 
exam ining the  topography of an  active site in  an  enzyme w hen catalysis 
occurs. Based on the  studies on the  possible b ind ing  sites in 
(acyl)carnitine, th e  conform ational stud ies on carn itine  and 
acety lcarn itine, and  the  analysis of th e  possible m echanism  for acyl 
transfer, we have designed the  reaction-in term ediate  analogues as shown 
in  F igure 1.2. The m orpholinium  ring  adopts a cha ir conformation. 
Therefore, the  N-C5-C6-0 torsion angle in  the  m orpholinium  ring  is
H
SC oA
I —R H  Y
Y =  H 
O H
C H - C o A
/  '
M e  M e
/  \
M e  M e
tetrahedral intermediate ttntilogue inhibit or
F igure 1.2. Proposed te trah ed ra l-in te rm ed ia te  and  analogue
inh ib ito r
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locked in  a  gauche (-) conform ation, w hich is sim ilar to N-C4-C3-0 torsion 
angle in  (acyl)carnitine. The carboxym ethyl and  the alkyl chain  (R) are 
cis d iequatoria l in  the  m ost stable conformation. A covalent bond (C2-C3) 
in  the m orpholinium  ring  replaces the  electrostatic  in teraction  betw een 
the negatively charged carbonyl oxygen and  the positively charged 
trim ethylam m onium  group in  the  reaction-in term ediate . A six-m em bered 
ring  was chosen because of ease of synthesis and  fewer conform ations.
Several conform ationally constrained  cyclic analogues, m ade in  th is 
laboratory, exhibit inh ib itory  activities tow ard d ifferent carn itine 
acy ltransferases . 1 6 >7 0 >7 9 >8 1  For exam ple, (+)-hem iacetylcarnitinium  (HAC, 
R = CHg, Y = OH, F igure 1.2) inh ib its  r a t  liver peroxisom al CAT and  ra t  
h e a r t m itochondrial CAT ; 7 0  (+)-hem ipalm itoylcarnitinium  (HPC, R = 
(CH 2 ) i 4 CH 3 , Y = OH) inh ib its  m itochondrial CPT-II and  peroxisom al COT 
of ra t  liv e r , 7 9  and  ra t  h e a r t and  r a t  liver m itochondrial CPT-I . 8 1
In  these  analogues, th e  location of Y (OH) is w here CoA a ttaches to 
the  proposed reaction-in term ediate. In  order to te s t th is  idea and  
increase the  potency of the  inhib itors, we need a p lan  to synthesize 
analogues w here Y = CH 2 -C 0 A.
1.4. PROJECT GOAL
The u ltim ate  goal of th is  project is to synthesize an  analogue, I, of 
th e  proposed te trahedral-reaction-in term ed ia te  for acetyl tran sfe r 
betw een carn itine and  CoA. This analogue contains both carn itine  and
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n h 2
OH
'()—P— O—P—O 
OH OH
,Me
OH
M e M e
P—O'IIO
I
CoA fragm ents (Y = CH 2 -C 0 A); those previously synthesized contain only 
the carn itine  fragm ent and  hydroxy group (Y = OH). The m orpholinium  
ring  in  th is  analogue contains two chiral centers, so th ere  are four 
stereoisom ers. The previously synthesized analogue inh ib ito rs are e ither 
racem ic m ixture or only one stereoisom er. The lab ility  of the hem iketal 
linkage allows the carbon to equilibrate  to the more stable 
configuration . 7 0  In  these  molecules, hydroxy group prefers to be axial. 
The goal of th is  project is to synthesize all the four stereoisom ers of the 
reaction-in term ediate analogue. By com paring the  inh ib itory  effects of 
these four stereoisom ers, more inform ation about the topographical 
a rran g em en t of the key recognition sites on the enzymes can be obtained. 
This inform ation will lead  to a three-dim ensional p icture of the  active 
sites of the  enzymes.
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1.5. SPECIFIC GOAL
The goal of my research  is to develop synthetic  stra teg ies for four
stereoisom ers of 6-carboxylatom ethyl-2-hydroym ethyl-2, 4, 4-trim ethyl 
m orpholinium , II, which are the  key synthetic in term ediates in  the 
proposed route to the four stereoisom ers of 2-(3-aminopropyl)-6- 
carboxylatom ethyl-2,4,4-trim ethylm orpholinium , III, which will serve as 
precursors to I. The assay of those synthesized enzyme inh ib ito rs by Drs. 
Noirfn Nic a B haird  and  R ena R. Ram say a t  UCSF is also a p a r t  of th is
work.
/  '
Me Me
/  \
Me Me
II m
C h a p t e r  II
SYNTHESES OF INHIBITORS OF
CARNITINE ACETYLTRANSFERASE
II. 1. RE TRO S YN THE TIC ANALYSIS
The syntheses of the target molecules can be approached from 
different pathways. Herein, we examine the structures of all the target 
molecules w ith different retro synthetic strategies to analyze the possible 
pathways to approach these molecules.
Both the target molecules II and III were disconnected into two m ain 
components: methyl 4-bromo-2-butenoate and P-hydroxyamine, which carries 
different functional groups for II and III and can be made in  different ways 
(Scheme II.1).
Me Me Y Me
X = OH Y = H, Me Z = OH
c h 2c h 2n h 2 c h 2c n
S ch em e II. 1
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II. 1.1. Target m olecule II
Two retro synthetic routes were proposed for synthesizing target 
molecule II, 6-carboxylatomethyl-2-hydroxymethyl-2, 4, 4-trimethyl 
morpholinium, as shown in  Scheme II. 2 .
'o,c
M e M e
OH
M e
n
Route B
OH
,Me
Route A
Br
M e M e
OH
,Me
I
M e
^O H
HOv p
/ \
6
O,
OH
OH
HO.
+
HN
M e
3 4
Schem e II.2
In retrosynthetic route A, m ethylation of the te rtia ry  amine, methyl 2- 
(6-hydroxymethyl-4,6-dimethylmorpholinyl)acetate, 2, followed by hydrolysis 
of m ethyl ester would give the target molecule II. Compound 2 is 
disconnected into two parts: methyl 4-bromo-2-butenoate, 3, and 3-
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methylamino-2-methylpropane-l,2-diol, 4. Compound 3 is commercially 
available. Compound 4 can be made by ring opening of 2-methylglycidol, 5, 
w ith methylamine. Compound 5 is commercially available for both R  and S 
configurations. Ring closure of 3 w ith (R)-4 or (S)-4 would give a 
diastereomeric m ixture of 2 , which could be separated by chromatography.
In retrosynthetic route B, 2-hydroxymethyl-6-(methoxycarbonyl)- 
methyl-2,4,4-trimethylmorpholinimn, 1, is disconnected into 3 and 3- 
dimethylamino-2-methylpropane-l,2-diol, 6 , which could be made from (R)-5 
and (S)-5 by ring opening w ith dimethylamine. In this route, m ethylation of 
tertiary  am ine is not needed. So it seems shorter th an  route A. But ring 
closure of 3 w ith (R)-6 or (S ) - 6  would give a diastereomeric m ixture of 
quaternary  amine salts, 1 , which m ight be much more difficult to separate 
th an  tertia ry  amine, 2 .
II.1.2. T a rg e t  m o lecu le  I I I
Schemes II.3, II.4, and II.5 show the retrosynthetic routes for 
synthesizing target molecule III, 2-(3-aminopropyl)-6-carboxylatomethyl- 
2 ,4,4-trim ethylm orpholinium .
In retrosynthetic route C (Scheme II.3), m ethylation of tertiary  amine 
of methyl 2-[6-(2-cyanoethyl)-4,6-dimethylmorpholinyl]acetate, 8 , followed by 
hydrolysis of methyl ester and reduction of cyano group would give the target 
molecule III. Compound 8  is disconnected into 3 and 5-methylamino-4- 
hydroxy-4-m ethylpentanenitrile, 9, which could be made by conversion of
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the hydroxy group of 5 into a cyanomethyl group and ring  opening of the 
epoxy with methylamine.
.NH,
,M e
M e M e
in
R oute  D
M e ()2C
CN,Me
R oute  C
M e  M e
C N,Me
N /  \  
1 0
CN
M e
8
* "T
H NI
M e
9
C N
OH
S ch em e II.3
In retrosynthetic route D (Scheme II.3), 2-(2-cyanoethyl)-6- 
(methoxycarbonyl)methyl-2,4,4-trimethylmorpholinium, 7, is disconnected 
into 3 and 5-dimethylamino-4-hydroxy-4-methylpentanenitrile, 10, which 
could be made the same way as compound 9 using dim ethylam ine in  place of 
methylamine. Ring closure of 3 w ith 10 would give a diastereomeric m ixture
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of quaternary  am ine salts 7, which m ight be much more difficult to separate 
than  compound 8 .
Scheme II.4 shows other retrosynthetic routes for m aking 10 and 9. 
Compounds 10 and 9 could be m ade by ring opening of 3-(l- 
m ethyloxiranyl)propanenitrile, 11, w ith dim ethylam ine and m ethylam ine 
respectively. Compound 11 could be derived from 3-methyl-3-buten-l-ol, 12, 
which is commercially available. In  these two routes, we have to resolve 11 
or 10 and 9.
In  Scheme II. 5, the ta rge t molecule III could be derived from II or 2, 
which could be m ade according to Scheme II. 2.
HN
Me
9
Schem e II.4
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11.1.3. S u m m ary
For target molecule II, both routes A and B originate from the same 
starting  m aterials, (R )- and (S)-2-methylglycidol, 5, which are commercially 
available. Chiral compounds (R )- and (S)-3-methylamino-2-methylpropane-
I,2-diol, 4, and (R)- and (S)-3-dimethylamino-2-methylpropane-l,2-diol, 6 , 
could be derived from these two chiral starting  m aterials. The ring closure 
products of methyl 4-bromo-2-butenoate, 3, w ith diols 4 or 6  would be 
m ixtures of diastereom ers 2 and 1, respectively. The diastereomeric m ixture 
of quaternary  amine salts, 1 , would be much more difficult to separate than  
the diastereomeric m ixture of tertiary  amines, 2. Therefore, route A would 
be better than  route B.
For target molecule III, both routes C and D originate from the same 
starting  m aterials. In route D, we would have the same problem as th a t in 
Scheme II. 2, route B for target molecule II — the separation of 
diastereomeric m ixture of quaternary  salts. In  the routes shown in  Scheme
II.4, we need to resolve 3-(l-m ethyloxiranyl)propanenitrile, 11, 5-
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methylamino-4-hydroxy-4-methylpentanenitrile, 9, or 5-dimethylamino-4- 
hydroxy-4-m ethylpentanenitrile, 10. If route A in  Scheme II.2 for target 
molecule II works well, the routes in  Scheme II.5 for target molecule III 
m ight work.
By routes C or D, we can build up the side chain (cyanomethyl) before 
the ring-closure step, which would have lower yield th an  the other steps 
because of potential side reactions and chrom atography to separate 
diastereomers. Therefore, we chose to work on routes C and D before A and 
B. Compound 5 is not optically pure and needs optical enrichm ent. B ut after 
the optical enrichm ent by converting it into 4-nitrobenzoate ester followed by 
recrystallization, it is very difficult to get it back. We have tried the route in 
Scheme II.4. Racemic 10 can be made from 12 and can be resolved as the 
3,5-dinitrobenzoate esters by HPLC using a chiral column. For preparative 
scale, th is resolution method is tedious and time consuming. Therefore, we 
have switched to routes A and B.
II.2. RESULTS AND DISCUSSION
Our synthetic efforts can be divided into two parts:
1) syntheses of (2R,6R)-, (2S,6S)-, (2R,6S)-, and (2S,6R)-Q- 
carboxylatomethyl-2-hydroxymethyl-2,4,4-trimethylmorpholinium, II.
2 ) syntheses of methyl (2S,6S]2R,6R)- and (2S,6R;2R,6S)-2-[6-(2- 
cyanoethyl)-4,6-dimethylmorpholinyl]acetate, 8 .
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II.2.1. Syntheses o f (2R,6R)-, (2S,6S )-, (2R,6S)-, and (2S,6R)-6- 
carboxylatomethyl-2-hydroxym ethyl-2,4,4- 
trim ethyhnorpholinium , II
The syntheses of four stereoisomers of 6 -carboxylatomethyl-2 - 
hydroxymethyl-2,4,4-trimethylmorpholinium, target molecule II, are 
illustrated  in Scheme II.6 .
CO., M e
1. Cl-PNB
O ,. /  C H ^ C L / E t .N  O h /  H ,N C H 3 H  \  sv'O H
i X ^ O H  -------- 2 - 3 -------| X  .O P N B  — 2---------------- 2*  . N .  .O H Br
2. recrystallization CH3OH ^  K ,C 0 3 /T H F
(A’)-5 (S)-13 (.S')-4
COOM C O O M e
1. D B U /T H F W►
2. column 
chromatography
(2/\, 6S)-2
C O O M e OH
O. .... "
(2S, 6S)-2
C O O M e OH
(2R, 6S)-2
CHd
E t.,0
C O O M e
NaOH 1
H .,0
(.2S , 6R)-1 
Schem e II.6
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According to the retrosynthetic analysis in  Scheme II.2, (R)- and (<S)-3- 
methylamino-2-methylpropane-l,2-diol, 4, could be made from OS)- and (R)-2- 
methylglycidol, 5, respectively by ring opening with m ethylam ine; (R)- and
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(S)-3-dimethylamino-2-methylpropane-l,2-diol, 6 , could be made from (S )- 
and (R)-2-methylglycidol, 5, respectively by ring opening w ith 
dimethylamine Compound 5 is commercially available for both R  and 
configurations.
Before starting  our synthesis, we m easured the optical purities of (inl­
and (S)-5 by iH  NMR analysis of the ir Mosher's esters . 8 2  We found th a t 
their optical purities were only about 90%. We needed the optical purities of 
our compounds to be greater than  97%. Therefore, the first step in  the 
synthesis was optical enrichm ent of 5. Gao et a l8 3  showed th a t the optical 
purity  of 5 can be improved by recrytallizing the 4-nitrobenzoate ester. As 
shown in  Scheme II.6 , compound 5 was readily converted into (1 - 
methyloxiranyl)methyl 4-nitrobenzoate, 13, by trea tm en t w ith 1 equivalent 
of 4-nitrobenzoyl chloride in dichloromethane in  the presence of 1 . 1  
equivalents of triethylam ine a t 0 °C. Successive recrystallizations from 
ethanol, diethyl ether, and isopropyl ether gave optically enriched ester 13 in  
49% yield.
The optical purity  of 13 was determ ined by l-H NMR analysis (Scheme
II.7). Compound 13 was converted into 6  by reaction with 4 equivalents of
/  H N M e , | V  sO H  C l-M T P A  ' V * ' 0 1 1  ~  *
L > \ ^ 0PNB  ► ^ N ^ X ^ O M T P A
M eO H  E t3N /C H 2C l2
13 6 15
S ch em e II. 7
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dim ethylam ine in  m ethanol. In this step, two reactions occur, ring opening 
of epoxide and cleavage of 4-nitrobenzoate, giving 6 . The product of the 4- 
nitrobenzoate ester cleavage was methyl 4-nitrobenzoate instead of N,N-
the reaction m ixture followed by filtration. Then compound 6  was converted 
into Mosher's ester 15 by trea tm en t w ith (R)-{+)-a-methoxy-a- 
(trifluoromethyl)phenylacetyl chloride (MTPA-C1). !H NMR analysis of 15 
indicated the optical purities of both (R )- and GSO-13 greater th an  97% (the 
m inor isomer was undetectable). Compound 6  was characterized by 
NMR, !3C NMR, FT-IR, m ass spectroscopy, and elem ental analysis.
After the optical enrichm ent, compound 5 could be recovered by 
hydrolysis of 13. Then ring  opening of 5 w ith m ethylam ine would give 4 
(Scheme II.8 ). So, two steps would be needed to convert 13 into 4. We 
thought th a t the ester bond of 13 could be cleaved by aminolysis with 
m ethylam ine, ju s t as i t  was from 13 to 6  w ith dim ethylamine, so th a t the 
cleavage of the ester bond and  ring opening of epoxy m ight take place in  one 
step. This way, we could save one step.
dimethyl 4-nitrobenzoate amide. This ester was removed by concentration of
.OPNB ►
(S)-I3 {R)-5 (S)-4
h 2n c h 3/c h 3o h
S ch em e II. 8
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Based on this idea, we tried the reaction of 13 w ith methylamine 
(Scheme II.8 ). A solution of 13 in  m ethanol was added into a solution of 6  
equivalents of m ethylam ine in  m ethanol a t room tem perature and the 
m ixture was stirred for 3 hours. A-Methyl 4-nitrobenzoate amide produced 
from the reaction was insoluble in m ethanol and was removed by 
concentration of the reaction m ixture followed by filtration. Compounds (R)- 
and (£>)-4 were obtained from (R)- and (S)-13 respectively in  75% yield and 
characterized by Bd NMR, 13C NMR, FT-IR, m ass spectroscopy, and 
elem ental analyses.
(.R)- and (S)-Methyl 4-[methyl-(2,3-dihydroxy-2-methylpropyl)amino]- 
2-butenoate, 14, were prepared by reaction of (R)- and (S)-4 with 1 
equivalent of methyl 4-bromo-2-butenoate in  the presence of potassium 
carbonate in THF a t room tem perature overnight (Scheme II.9). At least 1 
equivalent of potassium  carbonate was needed to neutralize hydrogen 
bromide produced from the reaction. After completion of the reaction, the 
precipitate was removed by filtration. Concentration of the solution gave 
crude product 14 in  83% yield, which was used for next reaction without
C O ,M e  C O O M e  O H
(S)-4 (S)-14
S ch em e II.9
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further purification. From *H NMR spectra of the crude product, we could 
see th a t the reaction was a little cleaner in  THF th an  in  diethyl ether. 
Compound 14 was characterized by 1H NMR, 13C NMR, FT-IR, and m ass 
spectroscopy.
Ring closure of 14 in  THF was catalyzed by 1,8- 
diazabicyclo[5.4.0]undec-7-ene (DBU)8  ^ to give methyl 2-(6-hydroxymethyl- 
4,6-dimethylmorpholinyl)acetate, 2 , as a  diastereomeric m ixture which was 
separated by column chrom atography (silica gel, 230-400 mesh, 
hexanes:dichlorom ethane:ethanol = 100:100:30) to give two diastereom ers 
w ith a  ratio of 3:1 and to tal isolated yield of 40% (Scheme 11.10). In this 
reaction, 6 -membered ring was formed instead of 7-membered ring because 6 - 
membered ring is more stable and easily formed th an  7-membered ring . 8 5  
The major isomer was the one with the (methoxycarbonyl)methyl and 
hydroxymethyl adopting trans positions. From (<S)-14, we got (2R,6S)- and 
(2S,6S)-2. From (R)-14, we got (2S,6R)- and (2R,6RY2. The four 
stereoisomers of 2 were characterized by !H NMR, 13C NMR, FT-IR, mass 
spectroscopy, and elem ental analyses.
C O O M e O H  C O O M e O H  C O O M e  OH
2. cnlum n 
chrom atography
CO-14 (2/?, 6.S')-2 (2S,  6.S')-2
Schem e 11.10
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The resulting stereoselectivity may be attribu ted  to chair transition  
structures in  the ring  closure reaction (Figure II. 1). The transition  structure 
on the righ t is more stable and easily formed th an  th a t on the left due to the 
intram olecular interaction between the hydrogen of hydroxy group and  the 
nitrogen. Therefore, the transition  structure on the right is favored and the 
m ajor isomer of the product is the one w ith the (methoxycarbonyl)methyl and 
hydroxymethyl adopting trans positions.
OH
OH
M e-----N
Me
H— O
Me N
5-* COoMe
OH
Me S+
F ig u re  II. 1. Transition structures for ring closure reaction of 14
Treatm ent of 2  w ith excess of iodomethane in  diethyl ether a t room 
tem perature gave 2-hydroxymethyl-6-(methoxycarbonyl)methyl-2,4,4- 
trim ethylm orpholinium  iodide, 1, as a light yellow solid in  74% yield. At 
least 15 equivalents of iodom ethane were needed for the completion of the 
reaction. Crystals for X-ray analysis were obtained by recrystallization from 
m ethanol by vapor diffusion w ith diethyl ether. The four stereoisomers of 1 
were characterized by *11 NMR, 13C NMR, FT-IR, m ass spectroscopy, and 
elem ental analyses, and  verified by single-crystal X-ray analyses (Figure II.2 
and II.3).
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In crystals, the morpholine ring of 1 is in  a  chair conformation. For 
(2R,6S)-1 and  its enantiom er (2S,6R)-1, the (methoxycarbonyl)methyl and 
methyl on C3 are cis; both occupy equatorial positions. For (2S,6S)-1 and its 
enantiom er (2R,6R)-1, the methoxycarbonylmethyl and hydroxymethyl are 
cis; both occupy equatorial positions. The (methoxycarbonyl)methyl always 
occupies an  equatorial position for all four stereoisomers.
Treatm ent of 1 w ith 1  equivalent of sodium hydroxide solution (0.1 N) 
gave the ta rge t molecule II, 6-carboxylatomethyl-2-hydroxymethyl-2,4,4- 
trim ethylm orpholinium , which was recrystallized from methanol/acetone 
(1/11) as colorless crystals in  67% yield. The four stereoisomers of II  were 
characterized by !H NMR, 13C NMR, FT-IR, m ass spectroscopy, and 
elem ental analyses, and verified by single-crystal X-ray analyses (Figure II.4 
and II.5).
In crystals, the morpholine ring of II  adopts a chair conformation. For 
(2R,6S)-I1 and  its  enantiom er (2S,6R)-II, the carboxylatomethyl and methyl 
on C3 are cis; both occupy equatorial positions. For (2S,6S)-II and its 
enantiom er (2R,6R)-II, the carboxylatomethyl and hydroxymethyl are cis; 
both occupy equatorial positions. The carboxylatomethyl always occupies an 
equatorial position for all four stereoisomers.
* The num bering system for the ORTEP drawings of the crystal structures is 
different from IUPAC nomenclature.
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Figure II.2. ORTEP drawing of (2S,£R)-2-hydroxymethyl-6- 
m ethoxycarbonylmethyl-2,4,4-trimethylmorpholinium iodide
Figure II.3. ORTEP drawing of (2R,6“R)-2-hydroxymethyl-6- 
methoxycarbonylmethyl-2,4,4-trimethylmorpholinium iodide
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Figure II.4. ORTEP drawing of (2R,6>£>)-6-carboxylatomethyl-2- 
hydroxymethyl-2,4,4-trimethylmorpholinium
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Figure II .5. ORTEP drawing of (2f?,fiR)-6-carboxylatomethyl-2- 
hydroxymethyl-2,4,4-trimethylmorpholinium
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II.2.2. Syntheses of m ethyl (2S,6S,2R,6R)- and (2S,6R#R,6S)-2-[6-(2- 
cyanoethyl)-4,6-dim ethylm orpholinyl]acetate, 8
11.2.2.1. Preparation of (i?S)-5-(Ar,Ar-dimethylamino)-4-hydroxy-4- 
m ethylpentanenitrile, (RS)-IO
Preparation of (/?«S)-5-(A^,iV-dimethylamino)-4-hydroxy-4-methyl-
pentanenitrile, 10, is shown in  Scheme 11.11.
First, 3-methyl-3-buten-l-ol, 12, was converted into 3-methyl-3- 
butenyl m ethanesulfonate, 16, by treatm ent w ith methanesulfonyl chloride 
in  dichloromethane a t 0 °C in  98% yield. Then treatm en t of 16 with sodium 
cyanide in  DMSO gave 4-methyl-4-pentenenitrile, 17, in  77% yield. 
Epoxidation 8 6  of 17 w ith monoperoxyphthalic acid (MMPP), m agnesium  salt 
hexahydrate, gave (f?S )-3-(l-m ethyloxiranyl)propanenitrile, 11, in  84% yield. 
Compound 1 1  could also be obtained by epoxidation of 17 w ith m- 
chloroperoxybenzoic acid (ra-CPBA ) . 8 7
H N M e ,
/-P rO H  / H 90 M e O H
11 10
Schem e 11.11
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By comparison w ith m-CPBA, MMPP is non-shock-sensitive and non­
deflagrating. Consequently, MMPP is much safer to use in  both small- and 
large-scale operations. In addition, both MMPP and the oxidation byproduct, 
m agnesium  phthalate, are water-soluble thus easily removed by extraction 
after completion of the reaction.
(RS)-5-(N,ALDimethylamino)-4-hydroxy-4-methylpentanenitrile, 1 0 , 
was obtained by ring opening of (R S)-ll  w ith dim ethylam ine in  m ethanol a t 
room tem perature in  90% yield. Compound 17 was identified by comparison 
of *H NMR and IR w ith lite ra tu re . 8 8  Compound 11 was identified by 
comparison of NMR w ith lite ra tu re . 8 ^ ’8 9  Compound 10 was characterized 
by *H NMR, 13C NMR, FT-IR, m ass spectroscopy, and elem ental analysis.
11.2.2.2. Optical resolu tion  of CRS)-5-dV,A/-dimethylainino)-4-hydroxy- 
4-m ethylpentanenitrile, (R S )-10
(RjS)-5-(iV,N-Dimethylamino)-4-hydroxy-4-methylpentanenitrile, 10, 
was resolved as the 3,5-dinitrobenzoate esters 18 by HPLC using a chiral 
column (Scheme 11.12). F irst, compound 10 was treated  w ith 3,5- 
dinitrobenzoyl chloride in  dichlorom ethane in  the presence of triethylam ine 
a t 0 °C to give a racemic m ixture of 18 in  100% yield. Then th is racemic 
m ixture was resolved by chiral column HPLC (CHIRALCEL OD column, 25 
cm x 2 cm, J. T. Baker Inc., hexanes:ethanol = 6 :1 ) to give two enantiom ers 
(R)- and (S)-18.
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After the optical resolution of 18, compounds (R)-10 and (<S)-10 could 
be obtained by aminolysis of CR)-18 and  (S)-18 respectively. We tried  the 
aminolysis reaction w ith (RS)-18. Dimethylamine (2 equivalents) was 
bubbled into a solution of (RS )-18 in  methanol. The reaction was completed 
w ithin h a lf an  hour, giving (i?S)-10 in  76% yield. (If we use GR)-18 or (S)-18, 
we shall get CR) - 1 0  or (<S)-1 0 .)
We tried  other methods to resolve compound 10, such as (a) making 
quaternary  ammonium salts w ith chiral acids (tartaric  acid, dibenzoyl 
ta rta ric  acid, 3-bromocamphor-9-sulfonic acid, W-acetyl-L-glutamic acid, 
mandelic acid, and malic acid) followed by recrystallization and (b) 
converting it into an  ester w ith a  chiral acid chloride ((2 S)-(+)-camphanic 
chloride). These methods did not work.
47
II.2.2.3. Preparation o f (R)- and (S)-5-(iV,iV-dimethylamino)-4- 
hydroxy-4-m ethylpentanenitrile, (R)- and (S)-10
Another route for preparation of (R )- and (S)-5-(Af,A-dimethylamino)-
4-hydroxy-4-methylpentanenitrile, 10, is shown in  Scheme 11.13.
Swern
Oi. /  oxidn
✓OH *0i>O
(/?)-5 (S)-I9
(E t0 )2P (0 )C H 2CN  
M eO L i Oi H N M e,
M eO H  /  C H 2C12 ^  " C N  M eO H
(/?)-20
OH
,N.
H , , P d / C
CN EtOH
(/<)-21 (.R)-H) 
Schem e 11.13
(72)-2-Methylglycidol, 5, was converted into CR)-3 -(l-m ethyloxiranyl)-2 - 
propenenitrile, 20, by Swern oxidation of 5 followed by W ittig reaction with 
diethyl cyanomethylphosphonate. The Swern oxidation reaction of 5 was 
conducted in  dichloromethane a t -50 to -60 °C (acetonitrile/acetone/dry ice 
bath) and 1.5 equivalents of oxalyl chloride and 3 equivalents of DMSO were 
needed for the completion of the reaction. After workup, (S)-(l- 
methyloxiranyl)formaldehyde, 19, was obtained as a solution in 
dichloromethane. Compound 19 was too volatile to separate from 
dichloromethane. Therefore, the solution was used directly for the W ittig 
reaction. Diethyl cyanomethylphosphonate was treated  with lithium  
methoxide in  m ethanol to generate phosphonate carbanion. Then, the 
solution of 19 in  dichloromethane was added. After stirring overnight at
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room tem perature, 20 was isolated in  43% yield. Compounds CR) - 2 0  and  (S)- 
20 were prepared from CR)-5 and  (S)-5 respectively and characterized by !H 
NMR and FT-IR.
Compounds (R)- and (S)-20 were treated  w ith dim ethylam ine in 
m ethanol to give (R )- and (S)-5-(A,N-dimethylamino)-4-hydroxy-4-methyl-2- 
pentenenitrile, 21, respectively in  89% yield, which were characterized by 
NMR and FT-IR. Catalytic hydrogenation (10% Pd on charcoal) of (R)- and 
(SO-21 in  absolute ethanol a t 25 psi and  room tem perature for 24 hours gave 
(R)- and (<S)-5-(N,N-dimethylamino)-4-hydroxy-4-methylpentanenitrile, 10, 
respectively in  87% yield.
By th is route, compounds (R)- and (S)-10 can be m ade from (R)- and 
(S)-5 respectively. But, as discussed a t the beginning of section II.2 .1 , both 
(R)- and (S)-5 are not optically pure. After optical enrichm ent by m aking the 
4-nitrobenzoate ester, 13, followed by recrystallization, how to regenerate 
compound 5 is still a challenge.
11.2.2.4. Attem pted preparation o f (R )- and (<S)-3-(l-methyloxiranyl) 
propanenitrile, (R)- and (S )- ll
We tried  to prepare (R)- and (S')-3-(l-methyloxiranyl)propanenitrile, 
11, from (R)- and (S)-5. As shown in  Scheme 11.14, compounds (R)- and (S)-5 
were converted into (S)- and  (R)-(1 -methyloxiranyl )methyl 4- 
nitrobenzenesulfonate, 22, by reaction w ith 4-nitrobenzenesulfonyl chloride 
in  dichloromethane in  the presence of triethylam ine a t 0 °C.
49
t > o
o„  /  c i s o 2^ n o 2 o
„OH ----------
CH2Cl2/Et3N L>O s02-<©>-N02 h I t  t ^ c N
22
Nal
HOAc
h 2o
-78°C
11
HO
K  34 X>SO K ^ ) ~ no2
23
S ch em e 11.14
Recrystallization of 22 from ethanol provided light yellow crystals. In  order 
to m easure the optical purity  of 22 by Mosher's ester analysis , 8 2  compound 
22 was converted into 2-hydroxy-3-iodo-2-methylpropyl 4- 
nitrobenzenesulfonate, 23, by reaction w ith sodium iodide in  acetic acid and 
w ater . 9 0  Crystals of 23 were obtained by recrystallization from methanol. 
U nfortunately, compound 23 could not be transform ed into Mosher's ester 
because it  is a  te rtia ry  alcohol. The conversion of 22 into 11 failed. K lunder 
et a l9 1  studied the reactivities of glycidyl arenesulfonate derivatives toward 
different organometallic reagents. In  most cases studied, ring opening 
occurred. Johnson and  D u tra 9 2  reported th a t tosylates and epoxy rings had 
sim ilar reactivities toward lith ium  diorganocuprates. Therefore, compounds 
(R )- and (<S) - 1 1  could not be prepared this way.
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Compounds 22 and 23 were identified by !H NMR and verified by 
single-crystal X-ray analyses.93,94
II.2.2.5. Structural analysis o f CR)-2-hydroxy-3-iodo-2-methylpropyl 
4-nitrobenzenesulfonate, CR)-23
For compound CR)-23 (Figure 11.6),^ we used PCMODEL9 5  to calculate 
the eighty-one possible staggered conformations of the four torsion-angle 
sequence—IC-C-C-O-SC^Ar. For the global minimum, those torsion angles 
are -58.9°, -55.2°, 169.3°, and  -83.6°, respectively. In the crystal, they are 
-57.7 (4)°, -61.7 (4)°, 171.2 (2)°, and -73.0 (3)°, respectively. In  this 
conformation, the I atom is on top of the benzene ring w ith nearly  equal 
distances between the I atom and six C atoms of the benzene ring. The 
intram olecular distance [4.083 (2) A] between I and the centroid of the aryl 
ring is alm ost equal to the sum  (3.90 A) of the van der W aals rad ius of I and 
the thickness of the benzene ring . 9 6  W ith respect to bond distances and 
angles, PCMODEL agrees approximately with the X-ray determ ination. 
Notable exceptions are the C1-C2, C7-C8, and C8-C9 bond lengths and the 
C7-C8-C9 and 05-N -06 bond angles, as well as m any values of the SO 3  
group. The X-ray results reveal th a t the 02-C3 bond is 0.049 A longer than  
the 01-C2 bond, which is consistent with OSC^Ar being a  better leaving 
group th an  the OH group. Molecules are linked in  chains along the 
crystallographic b axis by weak interm olecular hydrogen bonds involving
Figure II.6. ORTEP drawing of (f?)-2-hydroxy-3-iodo-2- 
methylpropyl 4-nitrobenzenesulfonate
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Oq.h  and Os=o- The 0 1 —0 3  distance is 2.927 (4) A and the O -H-O angle is 
165 (4)°.
II.2.2.6. Syntheses o f m ethyl (2S,6S;2R,6R)- and (2S,6R,2R,6S)-2-[6-(2- 
cyanoethyl)-4,6-dimethylm orpholinyl] acetate, 8
Methyl (2S,6S;2R,6R)- and (2S,6R;.2R,6S)-2-[6-(2-cyanoethyl)-4,6-
dimethylmorpholinyljacetate, 8 , were synthesized starting  from (RS)-5-(N,N-
dimethylamino)-4-hydroxy-4-methylpentanenitrile, 10, as shown in Scheme
11.15.
C O O M e C O O M e C O O M e
PliSH
2. M eO H
colum n
S i0 2 
E tO A c/M eO H
Schem e 11.15
Racemic m ixture of 10 reacted with 1  equivalent of methyl 4-bromo-2- 
butenoate in nitrom ethane a t 50 to 60 °C for 3 horn's. Then solvent was 
changed to m ethanol and refluxed for 18 hours. In  nitrom ethane, 
condensation of 10 with 3 took place to produce acyclic quaternary  amine
C O O M e C O O M e
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salt. In m ethanol, ring closure reaction occurred. The ring closure reaction 
cannot be carried out in  THF, as in  the reaction of 14, due to the insolubility 
of the acyclic interm ediate. Concentration of the reaction m ixture followed 
by w ashing w ith diethyl e ther and drying under vacuum gave crude product 
(2iS,,^S;2JR,6/2;2S,6Z2;2i2,dS)-2-(2-cyanoethyl)-6-(methoxycarbonyl)methyl- 
2,4,4-trimethylmorpholinium bromide, 7, in quantitative yield. This m ixture 
of four stereoisomers could not be separated by norm al-phase HPLC because 
they were quaternary  am ine salts. We tried reversed-phase HPLC to 
separate the two pairs of racem ates, (2R,6R\2S,6S)-1 and {2S,6R\2R,6S)-1, 
and we failed. The *H NMR spectrum  of 7 was too complicated to in terpret 
because it was a m ixture of four stereoisomers. Therefore, the crude m ixture 
of 7 was used for next reaction w ithout fu rther purification, separation, and 
characterization.
Crude 7 was treated  w ith 3 equivalents of thiophenol in  N,N- 
dim ethylethanolam ine 9 7  a t 70 °C to give methyl (2S,6S',2R,6R;2S,6R',2R,6S)-
2-[6-(2-c.yanoethyl)-4,6-dimethylmorpholinyl]acetate, 8 , which was separated 
by column chrom atography to give two racemic m ixtures, (2S,6S;2R,6R)-8 as 
a solid and (2S,6R]2R,6S)-8 as an  oil, w ith a ratio of 3:4 and total yield of 
25%. The low yield of the dem ethylation reaction may be caused mainly by 
the attack of thiophenol on the ester group of 7.98>" The ratio of the two 
racemic m ixtures indicates th a t the stereoselectivity of the ring closure 
reaction is not significant. The slight preference for (2S,6R;2i?,6S)-7 over 
{2R,6R\2S,6S)-7 m ay be a ttribu ted  to chair transition  structures in  the ring
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closure reaction (Figure II.7). The 2-cyanoethyl group is bigger than  methyl 
group and tends to be cis with (methoxycarbonyl)methyl so th a t both 
cyanoethyl and (methoxycarbonyl)methyl can adopt equatorial positions. 
Crystals of (2S,6S;2R,6R ) - 8  for X-ray analysis were obtained by 
recrystallization from hexanes. Compounds (2S,6S;2R,6R)-S and 
(2S,6R;2R,6S)-8 were characterized by NMR, 13C NMR, FT-IR, mass 
spectroscopy, and elem ental analyses.
Figure II.7. Transition structures for ring closure reaction of 10
The structure of (2S,6S]2R,6R ) - 8  was verified by single-crystal X-ray 
analysis (Figure II.8 ) . l "  The morpholine ring is in  a chair conformation. 
The methoxycarbonylmethyl and methyl on C3 are cis; both occupy 
equatorial positions, as does the IV-methyl group. We used PCMODEL9 5  to 
calculate the eighty-one possible staggered conformations of the four torsion- 
angle sequence—NC-CH 2 -CH 2 -C-0 and  0-CH-CH 2 -C(0)-0CH 3. For the 
global minimum, which was also found by GMMX , 1 0 1  those torsion angles 
are 179.2°, -50.5°, -60.0°, and 140.2°, respectively. In the crystal, they are
C N
M e  1'
+
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Figure II.8. ORTEP drawing of ( .^S,)dS;2R,dR)-2-[6-(2-cyanoethyl)-4>6-
dim ethylmorpholinyl]acetate
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-170.0 (1)°, -45.9 (2 )°, -71.6 (2)°, and  142.8 (1)°, respectively. W ith respect to 
bond distances and angles, PCMODEL also agrees w ith the X-ray 
determ ination.
In th is synthetic route, if  we s ta rt w ith (R )- or (S)-5-(N,N-
dim ethylam ino)-4-hydroxy-4-methylpentanenitrile, 10, which can be 
obtained by optical resolution, in  place of CRS)-1 0 , we shall be able to get the 
four stereoisomers of 8  separated (Scheme 11.16).
'CN
(7?)-10 (S) - 1 0
N \✓ N \✓ N
C O O M eC O O M e C O O M e C O O M e
(2S,  67?)-8 (27?, 67?)-8 (.2S , 6 .S')-8 (27?, 6S)-8
Schem e 11.16
11.2.3. Summary
(.2R,6R)-, (2S,6S )-, (2R,6S)-, and (2 S ,6 i?)-6 -carboxylatomethyl-2 - 
hydroxjnnethyl-2,4,4-trimethylmorpholinimn, target molecule II, and methyl
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(2S,6S]2R,6R)- and C2S,6R;2.R,6S)-2-[6-(2-cyanoethyl)-4,6-dimethyl- 
morpholinyl]acetate 8  were synthesized. (i?S)-5-(A^A^-Dimethylamino)-4- 
hydroxy-4-m ethylpentanenitrile, 10, was resolved.
The method for synthesizing target molecule II in  section II.2.1 can be 
fu rther extended for synthesizing a series of other inhibitors by changing 
hydroxy group of 2, 1 or target molecule II to other groups, which will be 
discussed in  C hapter IV. Target molecule III can also be approached by this 
strategy so th a t the ultim ate goal of th is project can be achieved.
By synthetic route in  section II.2.2, we got compound 8 , from which 
target molecule III can be derived. But by this route we cannot get other 
inhibitors which can be obtained by the extension of the method for 
synthesizing target molecule II (see C hapter IV).
II.3. EXPERIMENTAL
II.3.1. General procedures
Uncorrected m elting points were m easured on an  Electrotherm al 
m elting point apparatus, ^H NMR spectra were recorded w ith a B ruker 
AMX 500, AM 400, AC 200, or AC 100 FT-NMR spectrometer a t 500, 400, 
200, or 100 MHz, respectively. 13C NMR spectra were recorded w ith a 
B ruker AC 200 FT-NMR spectrom eter a t 50 MHz. Unless noted otherwise, 
all NMR spectra were recorded in  CDCI3 . Proton chemical shifts are 
expressed in  parts  per million (ppm) down field from in ternal 
tetram ethylsilane (TMS); coupling constants th a t were verified using PANIC
(Param eter Adjustm ent in  NMR by Iteration Calculation) are listed as J ; 
observed coupling constants not verified are listed as J app', all coupling 
constants are reported in  Hz. 13C chemical shifts are also expressed in  ppm 
relative to the solvent chemical shift. Assignments of the *H and 13C NMR 
signals were made by comparison w ith sim ilar known compounds and using 
DEPT, 2D 1 3 C-1H correlation, and 2D *H COSY experiments. Infrared 
spectra were recorded on a  Perkin Elm er 1760X FT-IR spectrometer as th in  
films on KBr cells and are reported in cm-1. Mass spectra were obtained with 
a Hewlett-Packard 5971A GC-MS. FAB MS samples were prepared by 
suspending in  glycerol and the spectra were recorded on a  F innigan TSQ 70. 
Elem ental analyses were performed by Oneida Research Services of 
Whitesboro, New York. The optical rotations were recorded in  a 3.5 x 1 0  mm 
or 10 x 100 mm cell w ith a JASCO DIP-370 digital polarimeter.
Unless otherwise noted, m aterials were obtained from commercial 
sources and used without fu rther purification. Tetrahydrofuran (THF) was 
distilled from potassium. Diethyl e ther was distilled from sodium-potassium 
alloy. Dimethyl sulfoxide (DMSO) was distilled from CaH 2  under reduced 
pressure and stored over Linde Molecular Sieves Type 3A in  a sealed brown 
bottle. Triethylam ine was distilled from CaH 2  and stored over Linde 
Molecular Sieves Type 3A. Dichloromethane was purified by shaking with 
concd H 2 SC>4 , w ashing w ith H 20  and satd  brine, drying w ith CaH2, 
distilling, and storing over 4A Molecular Sieves. M ethanol was distilled over 
a small am ount of Mg. 3,5-Dinitrobenzoyl chloride, 4-nitrobenzoyl chloride,
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and 4-mtrobenzenesulfonyl chloride were recrystallized from hexanes. 
Thionyl chloride was distilled before use. Methyl 4-bromo-2-butenoate was 
purified by vacuum distillation.
The organic solutions were dried (M gSO^ and concentrated by rotary 
evaporation unless otherwise noted.
II.3.2. Procedures
(/?)-(l-M ethyloxiranyl)m ethyl 4-nitrobenzoate (CR)-13). A
solution of 4-nitrobenzoyl chloride (116 mmol, 21.6 g) in  CH 2 CI2  (30 mL) was 
slowly added to a stirred m ixture of (S')-2-methylglycidol (110 mmol, 9.98 g, 
97% purity) and EtgN (124 mmol, 12.6 g) in  CH 2 Cl2  (90 mL) a t 0 °C (ice- 
w ater bath). The reaction m ixture was stirred  for additional 2  h  a t 0  °C. The 
reaction m ixture was diluted with cold CH 2 CI2  (60 mL) and filtered with 
suction to remove precipitated ammonium salt, which then was washed with 
cold CH 2 CI2  (3 x 15 mL). The m other liquor was washed w ith cold 5% HC1 
(60 mL), cold H 20  (2 x 40 mL), and dried. Concentration of the solution gave 
25.54 g of a light yellow solid. Recrystallization from EtOH (300 mL) gave 
19.81 g of light yellow crystals. The crystals were dissolved in  E t20  (250 mL) 
while refluxing and then  the solution was cooled slowly to 1 0  °C, giving 15.65 
g of crystals, which were then recrystallized from (i-Pr)20  (130 mL) to give 
12.8 g (49 %, ee > 97%) of (R)-13 (mp 87.5-89.0 °C, L it . 8 3  85.5-86.5 °C).
1H NMR (200 MHz; Lit.83): 1.49 (s, 3 H, CH z-), 2.76 (d, 1 H, tf-CH=oxirane, 
J app = 4.6), 2.87 (d, 1  H, H-CH=oxirane, J app = 4.5), 4.24 (d, 1  H, H-
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CHOCOAr, J app = 11.9), 4.58 (d, 1 H, tf-CHOCOAr, J app = 12.0), 8.21-8.34 
(m, 4 H, Bz). [a]23D -5.85° (c 2.035, CHC13, 10 x 100 mm cell. L it . 3 3  -5.87°). 
(S)-13 was prepared from 0R)-2-methylglycidol the same way as CR)-13. mp 
87.5-89.0 °C. [a]23D +5.83° (c 1.989, CHC13  10 x 100 m m  cell).
(7?)-3-Methylamiiio-2-methylpropane-l,2-diol (CR)-4). A solution 
of Cff)-13 (100 mmol, 23.7 g) in MeOH (200 mL) was added dropwise to a 
solution of H 2 NMe (0.6 mol, 18.6 g) in MeOH (60 mL). The m ixture was 
stirred for 3 h. The precipitate was removed by filtration. The solution was 
placed in  a refrigerator (0 °C) for 0.5 h  then  in  a  freezer for 1  h. Again, the 
precipitate was removed by filtration. The solution was concentrated until a 
large am ount of precipitate appeared and then  placed in  a freezer for 0.5 h. 
Again, the precipitate was removed by filtration. The solution was 
concentrated and then placed under vacuum. The residue was distilled 
under vacuum affording 8.92 g (75%) of CR)-4 as a colorless oil ( bp 80 °C/0.2 
Torr, 160 °C/17 Torr).
1H NMR (200 MHz): 1.10 (s, 3 H, CH 3 -C), 2.44 (s, 3 H, CH 3 -N), 2.66 (d, 1 H, 
H-CHN, J app = 12.1), 2.74 (dd, 1 H, H-CHN, J app = 12.2, 1.4), 3.48 (dd, 1 H, 
H-CHOH, J app = 11.2, 1.4), 3.65 (d, 1 H, H-CHOH, J app = 11.0). 13C NMR:
23.2 (CH 3 -C), 36.9 (CH 3 -N), 60.9 (-CH2 -N), 70.9 (C-OH), 71.2 (-CH2 OH). IR: 
3321 (OH), 1055 (C-N). MS m /e  (relative intensity): 8 8  (11.4), 75 (3.6), 70 
(7.3), 58 (10.4), 57 (4.3), 45 (5.1), 44 (100), 43 (1 0 .2 ), 42 (1 1 .1 ). Anal. Calcd 
for C5 H 1 3 N 0 2: C, 50.42; H, 10.92; N, 11.76. Found: C, 50.14; H, 11.02; N, 
11.57.
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(iS')-4 was prepared from CR)-13 the same way as CR)-4. Anal. Found: C, 
50.29; H, 10.89; N, 11.56.
(R)-Methyl 4-[methyl-(2,3-dihydroxy-2-methylpropyl)amino]-2- 
butenoate (CR)-14). A solution of methyl 4-bromo-2-butenoate (40.34 mmol,
7.22 g) in  THF (30 mL) was added to a m ixture of (R)-4 (40.34 mmol, 4.80 g) 
and K2 CO3  (54 mmol, 7.4 g) in  THF (50 mL). The reaction m ixture was 
stirred overnight and  then  filtered. The solution was concentrated and then 
placed under vacuum. Dry E t 2 0  (40 mL) was added and the precipitate was 
removed by filtration. Concentration of the solution gave 7.26 g (83%) of a 
light yellow oil, which was used for next reaction w ithout further 
purification.
!H NMR (200 MHz): 1.07 (s, 3 H, CH 3 -C), 2.38 (s, 3 H, CH 3 -N), 2.49 (d, 1 H, 
H-CHC(OH)(CH 3 )CH2 OH, J app = 13.8), 2.62 (d, 1 H, H-
CHC(OH)(CH3 )CH2 OH, J app = 13.8), 3.13-3.63 (m, 4 H, H 2 C-CH=CH-, H 2C- 
OH), 3.73 (s, 3 H, CH 3 -O), 5.90-6.00 (m, 1 H, H C -C 0 2 CH3), 6.85-6.99 (m, 1  
H, HC=CH-C0 2 CH3). 13C NMR (50 MHz): 23.7 (CH 3 -C), 45.0 (CH 3 -N), 51.6 
(CH 3 O), 60.4 (CH 2 -CH=CH), 65.4 (N-CH 2 -COH), 70.2 (CH2 -OH), 71.5 (C- 
OH), 123.2 (=CH-C0 2 CH3), 144.9 (CH=CHC0 2 CH3), 166.4 (C 0 2 CH3). IR: 
3425 (OH), 1724 (C=0), 1660 (C=C). MS, FAB, m /e : 218 (M++1).
(iS)-14 was prepared from (S)-17 the same way as (i?)-14.
M ethyl (2S,6'i?)-2-(4,6-dimethyl-6-hydroxymethylmorpholinyl) 
acetate ((2S,6R)-2) and m ethyl (2i2,fiR)-2-(4,6-dimethyl-6-hydroxy- 
m ethylm orpholinyl) acetate ((2R,6R)-2). DBU (2.5 mL, 16.4 mmol) was
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added to a solution of crude CR)-14 (33.4 mmol, 7.26 g) in  THF (500 mL). The 
reaction m ixture was stirred  a t r t  for 24 h. Concentration of the solution 
gave a brown liquid, which was purified by column chrom atography (S i02, 
70-230 mesh, sample:Si0 2  = 1:25, EtOAc:MeOH = 100:5), yielding a  m ixture 
of two diastereomers. The diastereom ers were separated by column 
chrom atography (S i0 2, 230-400 mesh, sample:Si0 2  = 1:70,
hexanes:CH 2 Cl2:EtOH = 100:100:30), giving (2S,6R)-2 (2.18 g, 30%) and 
(2R,6R)-2 (0.70 g, 9.6%).
(2S,6R)-2:
1H NMR (500 MHz): 1.11 (s, 3 H, CH 3 -C6 ), 1.74 (dd, 1 H, H(ax)-C3, J  = 
10.87, 10.73), 1.94 (d, 1 H, H(ax)-C5, J  = 11.83), 2.20 (s, 3 H, CH 3 -N), 2.37 
(dd, 1 H, # -C H C 0 2 CH3, J  = 16.35, 4.06), 2.49 (dd, 1 H, H -C H C 0 2 CH3, J  = 
16.35, 8.93), 2.65 (d, 1 H, H(eq)-C5, J  = 11.83), 2.70 (d, 1 H, H(eq)-C3, J  = 
10.87), 3.40 (d, 1 H, H-CHOH, J  = 11.58), 3.70 (s, 3 H, CH 3 -0), 4.20 (d, 1 H, 
H-CHOH, J  = 11.58), 4.29-4.37 (m, H-C2). 13C NMR: 23.6 (CH 3 -C), 38.2 
(CH 2 -C 0 2 CH3), 45.9 (CH 3 -N), 51.7 (CH 3 -0), 58.8 (C3), 61.3 (C5), 65.8 (CH2- 
OH), 6 6 . 6  (C2), 73.5 (C6 ), 171.5 (C=0). IR: 3506 (OH), 1741 (C=0). MS m /e 
(relative intensity): 217 (19.5), 186 (54.5), 144 (13.7), 143 (26.5), 142 (31.6), 
128 (17.6), 114 (10.5), 98 (18.4), 70 (25.1), 59 (16.9), 58 (17.6), 57 (21.5), 44 
(47.9), 43 (100), 42 (60.4), 41 (27.0). [a]23D, -20.2° (c 9.95, CHC13, 3.5 x 10 
mm cell). Anal. Calcd for C 1 0 H 1 9 NO4 : C, 55.30; H, 8.76; N, 6.45. Found: C, 
54.98; H, 8.73; N, 6.47.
(2R,6R)-2:
*H NMR (500 MHz): 1.29 (s, 3 H, C tf3 -C6 ), 1.68 (dd, 1 H, H(ax)-C3, J  = 
11.08, 10.96), 2.09 (d, 1 H, H(ax)-C5, J  = 10.95), 2.24 (s, 3 H, CH 3 -N), 2.39 
(dd, 1 H, H -CH C0 2 CH3, J  =15.30, 5.74), 2.42 (d, 1 H, #(eq)-C5, J  = 10.95), 
2.48 (dd, 1  H, H-CHCO 2 CH 3 , J  = 15.30, 7.11), 2.75 (d, 1 H, H(eq)-C3, J  = 
11.08), 3.33 (d, 1  H, tf-CHOH, J  = 11.23), 3.47 (d, 1  H, tf-CHOH, J  = 11.23),
3.69 (s, 3 H, CH 3 -O), 4.21-4.27 (m, 1 H, H-C2). NMR: 18.7 (CH3 -C), 38.9 
(CH 2 -CO2 CH 3 ), 46.4 (CH3 -N), 51.6 (CH 3 -O), 59.3 (C3), 59.7 (C5), 66.5 (C2),
69.2 (CH2 -OH), 74.3 (C6 ), 171.1 (C=0). IR: 3452 (OH), 1741 (C=0). MS m /e  
(relative intensity): 217 (21.1), 186 (56.2), 144 (16.1), 143 (26.5), 142 (37.4), 
128 (15.0), 114 (13.3), 98 (17.7), 84 (84.8), 70 (26.0), 59 (15.6), 58 (12.7), 57 
(19.2), 44 (48.3), 43 (100), 42 (40.7), 41 (15.3). [a]23D, +2.24° (c 1 1 .6 , CHCI3 ,
3.5 x 10 min cell). Anal. Calcd for C 1 0 H 1 9 NO4 : C, 55.30; H, 8.76; N, 6.45. 
Found: C, 54.90; H, 8.45; N, 6.33.
(2R,6S)-2, (2S,6S)-2 were prepared from (S)-14 the same way as (2S,6R)-2 
and (2R,6R)-2.
(2R,6S)-2:
[oc]23d  +20.6° (c 5.93, CHCI3 , 3.5 x 10 mm cell). Anal. Found: C, 54.98; H, 
8.45; N, 6.46.
(2S,6S)-2 :
[a]23£> -2.26° (c 9.28, CHCI3 , 3.5 x 10 mm cell) . Anal. Found: C, 54.92; H, 
8.50; N, 6.34.
(2/?,67S)-2-Hydroxymethyl-6-methoxycarhonylmethyl-2,4,4-tri- 
m ethylm orpholinium  iodide (C2R,ftS)-l). To a solution of (2S,6R)-2
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(0.868 g, 4 mmol) in  dry E t 2 0  (30 mL) was added CH 3 I (5 mL, 80 mmol). The 
m ixture was placed in  the dark  and stirred  for 3 d. The solution was 
decanted and the precipitate was washed with dry E t 2 0  ( 3 x 5  mL). The 
yellow paste was dried under vacuum  to give 1.06 g (74%) of a  light yellow 
solid which was used for the next reaction w ithout fu rther purification. 
Crystals for X-ray analysis were obtained by recrystallization from MeOH by 
vapor diffusion w ith E t 2 0 .
(2R,6S)-1 (mp 136.5-140 °C, dec.):
!H NMR (400 MHz, CD3 OD, TMS): 1.27 (s, 3 H, CH 3 -C2), 2.60 (dd, 1 H, H- 
C H C 0 2 CH3, J  = 16.13, 7.08), 2.65 (dd, 1 H, H -CH C 0 2 CH3, J  = 16.13, 5.04), 
3.13 (d, 1 H, H{ax)-C3, J  = 13.39), 3.26 (dd, 1 H, H(ax)-C5, J  = 11.91, 12.82),
3.30 (s, 3 H, CH 3 (eq)-N), 3.36 (s, 3 H, CH 3 (ax)-N), 3.56 (d, 1 H, H-CHOH, J  = 
11.69), 3.63 (ddd, 1H, #(eq)-C5, J  = 12.82, 1.56, 1.49), 3.71 (s, 3 H, CH30), 
3.83 (dd, H(eq)-C3, J  = 13.39, 1.56), 3.95 (d, 1 H, H-CHOH, J  =11.69), 4.63-
4.70 (m, 1 H, H-C6). 13C NMR (CD3 OD): 26.94 (CH 3 -C2 ), 38.31 (CH2-
C 0 2 CH3), 51.52 (CH 3 (ax)-N), 52.56 (CH 3 0), 59.53 (CH 3 (eq)-N), 63.74 (C3, 
C6 ), 63.96 (C5), 64.10 (CH 2 OH), 74.98 (C2), 171.72 (C 0 2 CH3). IR: 3346 
(OH), 1734 (C=0), 1058 (C-O-C). MS, FAB, m/e: 232 (M-L). [a]22D -21.3° (c 
7.10, MeOH, 3.5 x 10 mm cell). Anal. Calcd for Cn H 2 2 N 0 4 I: C, 36.77; H, 
6.13; N, 3.90. Found: C, 36.64; H, 6 .0 2 ; N, 3.87.
(2R,6R)-1, (2S,6S)-1, and (2S,6R)-1 were prepared the same way as {2R,6S)~ 1 
from (2R,6R)-2, (2S,6S)-2, and  (2R,6S)-2 respectively.
(2R,6R)-1 (mp 136.2-140 °C, dec.):
1H NMR (400 MHz, CD3 OD, TMS): 1.45 (s, 3 H, CH 3 -C2), 2.63 (dd, 1 H, H- 
C H C0 2 CH3, J  = 15.38, 8.41), 2.67 (dd, 1 H, H -CH C 0 2 CH3, J  =15.38, 4.91), 
3.20 (dd, 1 H, H(ax)-C5, J  = 12.05, 11.74), 3.31 (s, 3 H, C # 3 (eq)-N), 3.34 (d, 1
H, iT-CHOH, J  = 11.71), 3.43 (s, 3 H, CH 3 (ax)-N), 3.45 (d, 1 H, tf(ax)-C3, J  
=13.74), 3.46 (d, 1 H, H-CHOH, J  = 11.71), 3.57 (dd, 1 H, H(eq)-C3, J  = 13.74,
I.84), 3.64 (ddd, 1 H, #(eq)-C5, J  = 11.74, 2.18, 1.84), 3.71 (s, 3 H, CH 3 0), 
4.61-4.68 (m, 1 H, H-C6 ). NMR (CD3 OD): 19.93 (CH 3 -C2), 38.13 
(CH 2 C 0 2 CH3), 51.90 (CH 3 (ax)-N), 52.49 (CH3 0), 59.74 (CH 3 (eq)-N), 63.21 
(C6 ), 64.34 (C5), 65.39 (C3), 69.92 (CH2 OH), 74.77 (C2), 171.62 (C 0 2 CH3). 
IR: 3359 (OH), 1735 (C=0), 1066 (C-O-C). MS, FAB, m /e : 232 (M-P). [a]22D 
+15.1° (c 9.90, MeOH, 3.5 x 10 mm cell). Anal. Calcd for C n H 2 2 N 0 4 l: C, 
36.77; H, 6.13; N, 3.90. Found: C, 36.67; H, 6.08; N, 3.85.
(2S,6S)-1:
[ a ] 2 2 D  -14.8° (c 9.25, MeOH, 3.5 x 10 mm cell). Anal. Found: C, 36.76; H, 
6.08; N, 3.84.
(2S,6R)-1:
[ a ] 2 2 D  +21.5° (c 6.40, MeOH, 3.5 x 10 mm cell). Anal. Found: C, 36.66; H, 
6.05; N, 3.84.
(2R,6VS)-6-Carboxylatomethyl-2-hydroxyinethyl-2,4,4-trimethyl 
m orpholinium  (C2R,ftS)-II). A solution of (2R,6S)-1 (0.95 g, ~ 2.6 mmol) in 
0.1 M NaOH (26 mL, 2.6 mmol) was stirred a t r t  overnight. The reaction 
m ixture was concentrated by rotary evaporation, then dried under vacuum. 
The residual solid was dissolved in CH 3 OH (30 mL) and filtered. The liquid
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was concentrated by rotary  evaporation and  dried under vacuum. The 
resulting light yellow solid was dissolved in  a m inim um  am ount of CH 3 OH, 
and acetone (~ 40 mL) was added. The solution was decanted and the 
precipitate was dried under vacuum. The solid obtained was dissolved in  
CH 3 OH (80 mL). Then acetone (900 mL) was added. The solution was left 
open to the a ir on the bench, yielding 0.44 g (67%) of colorless crystals 
(C 1 0 H 1 9 NO 4 -2H2 O).
(2R,6S)-ll (mp 230-231 °C):
XH NMR (400 MHz, CD3 OD, TMS): 1.26 (s, 3 H, CH 3 -C2), 2.30 (dd, 1 H, H- 
C H C 0 2 CH3, J  = 15.34, 6.44), 2.46 (dd, 1 H, H -C H C 0 2 CH3, J  = 15.34, 6.61), 
3.06 (d, 1 H, H(ax)-C3, J  = 13.40), 3.11 (dd, 1 H, #(ax)-C5, J  = 12.55, 11.79),
3.23 (s, 3 H, GfiT3 (eq)-N), 3.30 (s, 3 H, C # 3 (ax)-N), 3.56 (ddd, 1 H, H(eq)-C5, J  
= 12.55, 1.79, 1.68), 3.64 (d, 1  H, tf-CHOH, J  = 11.80), 3.75 (dd, 1 H, H(eq)- 
C3, J  = 13.40, 1.79), 3.87 (d, 1  H, H-CHOH, J  = 11.80), 4.49-4.57 (m, 1 H, H- 
C6 ). 13C NMR ( CD3 OD): 26.84 (CH 3 -C2), 42.21 (CH2 C 0 2 CH3), 51.24
(CH3 (eq)-N), 59.25 (CH3 (ax)-N), 63.89 (CH 2 OH, C5), 64.92 (C6 ), 64.99 (C3), 
74.65 (C2 ), 176.94 (C 02‘). IR: 3387 (OH), 1586 (C=0), 1061 (C-O-C). MS, 
FAB, m /e: 218 (M++1). [a]22D -23.1° (c 6.50, MeOH, 3.5 x 10 mm cell). Anal. 
Calcd for C i0 H 1 9 NO 4 -2H2 O: C, 47.43; H, 9.09; N, 5.53. Found: C, 47.78; H, 
8.93; N, 5.46.
C2i?,6R)-II, (2S,6S)-1I, and (2S,6“i?)-II were prepared the same way as 
(2R,6S)-II from (2R,6R)-1, (2S,6S)-1, (2S,6R)-1 respectively.
(2R,6R)-II (mp 235.5-236.5 °C):
!H NMR (400 MHz, CD3 OD, TMS): 1.42 (s, 3 H, CH 3 -C2), 2.34 (dd, 1  H, H- 
C H C0 2 CH3, J  = 14.82, 6.43), 2.45 (dd, 1 H, H -C H C 0 2 CH3, J  = 14.82, 6.26), 
3.09 (dd, 1 H, H{ax)-C5, J  = 12.26, 11.26),3.24 (s, 3 H, CH 3 (eq)-N), 3.30 (d, 1  
H, H{ax)-C3, J  = 11.90), 3.35 (s, 3 H, CH 3 (ax)-N), 3.42 (s, 2 H, CH 2 OH), 3.46 
(d, 1 H, #(eq)-C3, J  = 11.90), 3.57 (d, 1  H, H(eq)-C5, J  = 12.26), 4.51 (m, 1 H, 
H-C6 ). 13C NMR (CD3 OD): 20.00 (CH3 -C2), 42.36 (CH 2 C 0 2 CH3), 51.65
(CH3 (eq)-N), 59.53 (CH3(ax)-N), 64.48 (C6 ), 65.23 (C5), 65.43 (C3), 70.06 
(CH2 OH), 74.44 (C2 ), 177.09 (C 02-). IR: 3583 (OH), 1587 (C=0), 1078 (C-O- 
C). MS, FAB, m /e : 218 (M++1 ). [a]22D +15.6° (c 4.8, MeOH, 3.5 x 1 0  mm 
cell). Anal. Calcd for C ig E Iig N O ^ H ^ : C, 47.43; H, 9.09; N, 5.53. Found: C, 
47.31; H, 8.83; N, 5.47.
(2S,6S)-II:
[a]22D -16.0° (c 5.00, MeOH, 3.5 x 1 0  mm cell). Anal. Found: C, 47.29; H, 
8.77; N, 5.57.
(2S,6R)-II:
[oe]22D +23.1° (c 5.40, MeOH, 3.5 x 10 mm cell). Anal. Found: C, 47.05; H, 
8.89; N, 5.34.
3 -M ethy l-3 -bu teny l m e th a n e s u lfo n a te  (16). A solution of 
m ethanesulfonyl chloride (0.42 mol, 49.0 g) dissolved in  CH 2 C12  (100 mL) 
was added dropwise to a  stirred  solution of 3-methyl-3-buten-l-ol (0.40 mol, 
35.50 g) and E t3N (0.60 mol, 60.6 g) in  CH2 C12  (400 mL) a t 0  °C (ice-water 
bath). After completion of the addition, the reaction m ixture was stirred  for 2 
h a t 0 °C. The reaction m ixture was diluted w ith cold CH 2 C12  (200 mL) and
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filtered w ith suction to remove precipitated ammonium salt which was then 
washed w ith cold CH 2 CI2  (100 mL). The m other liquor was washed w ith cold 
5% HC1 (200 mL), cold H 2 O ( 2  x 150 mL), and dried. Concentration of the 
solution gave 64.29 g (98%) of a brown oil, which was used w ithout further 
purification.
1H NMR (200 MHz; Lit. 102); 1.78 (s, 3 H, C tf 3 -C=C), 2.47 (t, 2  H, -C # 2 -C=C, 
Japp = 6 .8 ), 3.01 (s, 3 H, C tf3 -S), 4.33 (t, 2  H, -CH2 -OS, J app = 6.9), 4.84 (m, 2  
H, CH2=C).
4-M ethyl-4-pentenenitrile (17). U nder N 2 , a solution of 16 (0.39 
mol, 64.29 g) in  DMSO (100 mL) was added dropwise to a stirred slurry of 
NaCN (0.60 mol, 31.9 g) in  DMSO (250 mL) a t 80 °C. After the completion of 
the addition, the reaction m ixture was stirred for 5 h  a t 80 °C, cooled, poured 
into ic e -^ O  (800 mL), and extracted with E t2 0  (4 x 800 mL). The combined 
extracts were washed w ith satd  brine (3 x 800 mL) and dried. Concentration 
of the soluton gave a yellow oil. Vacuum distillation afforded 28.68 g (77%) 
of a colorless oil (bp 65-66 °C/17 Torr; L it . 8 8  50-52 °C/12 Torr).
!H NMR (200 MHz; Lit.88): 1.77 (s, 3 H, Cff3-), 2.30-2.55 (m, 4 H, 
CH2CH2C m , 4.80-4.88 (m, 2  H, CH2=C). 13C NMR: 15.5 (C2), 21.7 (CH3),
32.7 (C3), 112.0 (C5), 119.1 (CN), 141.4 (C4). IR (Lit.88): 3081 (olefinic C-H 
stretch), 2247 (C=N), 1653 (C=C stretch), 898 (olefinic C-H bend).
CRS)-3-(l-M ethyloxiranyl)propanenitrile (11). A solution of 
monoperoxyphthalic acid, m agnesium  salt hexahydrate (70 mmol, 43.30 g, 
80% purity) in  H 2 O (200 mL) was added dropwise to a  solution of 17 (100
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mmol, 9.50 g) in i-PrOH (60 mL). The m ixture was stirred  for 5 h  a t rt. After 
addition of H 2 O (100 mL), the reaction m ixture was extracted w ith CH 2 CI2  (3 
x 150 mL). The combined extracts were washed w ith 1 M N a 2 S 0 3  (100 mL), 
10% N a 2 CC> 3  (100 mL), H 2 O ( 2  x 200 mL), dried, and concentrated affording 
a  colorless oil. Vacuum distillation yielded 9.32 g (84%) of a colorless oil (bp 
83-84 °C/17 Torr; L it . 8 9  110 °C/25 Torr).
XH NMR (200 MHz, Lit.8?): 1.36 (s, 3 H, CH 3-), 1.95 (t, 2 H, -CH 2 CH 2 CN, 
J app = 7.4), 2.43 (t, 2 H, CH 2 CN, J app = 7.6), 2.64 (d, 1 H, H-CH=oxirane, 
J app = 4.4), 2.72 (d, 1 H, F-CH=oxirane, J app = 4.3). *H NMR (200 MHz, 
C6 D6; Lit.89): 0.84 (s, 3 H, Cff3-), 1.20-1.64 (m, 4 H, C # 2 CH 2 CN), 2.07 (d, 1  
H, H-CH=oxirane, J app = 4.7), 2.13 (d, 1  H, H-CH=oxirane, J app = 4.7). 13C 
NMR: 12.4 (C2), 20.1 (CH3), 31.6 (C3), 52.8 (CH2 =oxirane), 54.8 (C=oxirane), 
119.0 (CN). IR: 3043 (oxirane), 2250 (O N ).
(/?S)-5-(Ar,A ?-D im eth y lam in o )-4 -h y d ro x y -4 -m eth y lp en tan e iiitr ile  
(10). A solution of 11 (52 mmol, 5.8 g) in  MeOH (14 mL) was added dropwise 
to a  solution of HNMe2  (74 mmol, 3.34 g) in  MeOH (20 mL). The m ixture 
was stirred  for 1.5 h  a t rt. Concentration of the reaction m ixture gave a light 
yellow oil. Vacuum distillation afforded 7.30 g (90%) of a colorless oil (bp 
103-104 °C/17 Torr).
!H NMR (100 MHz): 1.13 (s, 3 H, C # 3 -C), 1.60-1.90 (m, 2 H, C # 2 CH 2 CN),
2.31 (s, 2  H, CJT2 -N), 2.38 (s, 6  H, (CH 3 )2 N-), 2.40-2.60 (m, 2  H, CH 2 CN). 13C 
NMR: 11.5 (C2), 24.8 (CH 3 -C), 35.6 (C3), 48.3 (CH 3 -N), 68.4 (C5), 70.5 (C4),
120.5 (CN). IR: 3483 (OH), 2248 (C=N), 1044 (N-C). MS m /e  (relative
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intensity): 156 (5.2), 141 (29.2), 102 (100), 87 (16.7), 59 54.2), 58 (27.6). Anal. 
Calcd for C8 H 1 6 N 2 0 : C, 61.49; H, 10.34; N, 17.93. Found: C, 61.27; H, 10.49; 
N, 17.61.
(/?<Sl)-3-Cyano-l-((dim ethylainino)niethyl]-l-m ethylpropyl 3,5- 
dinitrobenzoate (18). A solution of 3,5-dinitrobenzoyl chloride (23 mmol, 
5.41 g) in  CH 2 CI2  (25 mL) was slowly added to a stirred  m ixture of 10 (21 
mmol, 3.28 g,) and E t3N (5 mmol, 0.50 g) in  CH 2 CI2  (30 mL) a t 0 °C (ice- 
w ater bath). After the addition was complete, the reaction m ixture was 
stirred for an  additional 2 h  a t 0 °C. The pH was adjusted to 12 w ith 5% 
NaOH. The phases were separated  and the aqueous solution was extracted 
with CH2 CI2  (2 x 25 mL). The combined CH 2 CI2  solutions were washed with 
H 20  ( 2  x 20 mL), dried, and concentrated to give 8.05 g (100%) of a brown oil. 
!H NMR (100 MHz): 1.69 (s, 3 H, CH 3 -C), 2.35 (s, 6  H, (CH 3 )2 N), 2.48-2.60 
(m, 4 H, CH2CH2CN), 2.79 (d, 1  H, H-CH-N, J app = 7.2), 2.89 (d, 1  H, H-CU- 
N, J app = 7.3), 9.11 (d, 2 H, o-H of benzoyl group, J app = 0.9), 9.22 (t, 1 H, p- 
H  of benzoyl group, J app = 1.0). IR: 3104 (aromatic), 2249 (C=N), 1728 
(C=0), 1087 (C-N).
R esolution of CR)-18 and (S)-18. Racemic m ixture of 18 was 
resolved by chiral column HPLC (CHIRALCEL OD column, 25 cm x 2 cm, J. 
T. Baker Inc., hexane:EtOH = 6:1, flowrate = 7 mL/min, injection size = 70 |i 
g, retention time: 93 min, 105 min), giving Cff)-18 and (SO-18. Absolute 
configurations were not determ ined.
IR and *H NMR spectra are the same as 18.
71
A m in o ly sis  o f 18. HNMe2  (45 mmol, 2.03 g) was bubbled into a 
solution of 18 (21 mmol, 7.35 g) in  MeOH (60 mL). The reaction m ixture was 
stirred a t r t  for 0.5 h and then  concentrated. The residue was taken  up in 
H 2 O (30 mL) and filtered to remove the light yellow solid iV,iV-dimethyl 3,5- 
dinitrobenzoate amide. The aqueous solution was extracted with CH 2 CI2  (3 x 
20 mL). The extract was dried and concentrated to give a yellow oil. Vacuum 
distillation afforded 2.49 g (76%) of 10 as a colorless oil.
(f2 )-3 -(l-M eth y lo x iran y l)-2 -p ro p en en itrile  ((U)-20). A solution of 
oxalyl chloride (0.18 mol, 22.86 g) in  CH 2 CI2  (180 mL) was placed in  a 1000 
mL 3-neck round-bottom flask equipped with a therm om eter, a CaS 0 4  drying 
tube, and  a dropping funnel and cooled to -50 to -60 °C 
(acetonitrile/acetone/C 0 2 ). A solution of DMSO (0.39 mol, 30.42 g) in  CH 2 CI2  
(60 mL) was added and stirred  for 5 min, followed by the addition of (R)-5 
(0.124 mol, 11.25 g) in  CH 2 CI2  (75 mL). S tirring was continued for an  
additional 20 min. EtgN (0.75 mol, 76 g) was added and the reaction m ixture 
was stirred  for 5 m in and then  allowed to warm  to rt. H 2 O (250 mL) was 
added and the aqueous layer was extracted w ith CH 2 CI2  (4 x 70 mL). The 
organic layers were combined, washed w ith satd  brine (100 mL), 10% HC1 (50 
mL), H 2 O (50 mL), 5% N a 2 CC> 3  (50 mL), and H 2 O (50 mL), and dried, which 
was assum ed to be a solution of (S)-( l-m ethyloxiranyl)formaldehyde ((S)-19) 
and CH 2 C12.
A solution of (Et0 )2 P(0 )CH2 CN (0.135 mol, 24.03 g) in MeOH (50 mL) 
was added under N 2  to a stirred  solution of C ^ O L i (0.135 mol) in  MeOH
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(prepared by adding 54 mL of 2.5 M solution of BuLi in  hexanes into MeOH 
(50 mL) a t 0 °C) m aintained a t 0 °C. Then the solution of (S)-19 (above) was 
added to the m ixture a t 0 °C. The reaction m ixture was stirred  a t r t  
overnight and then quenched with H 2 O (50 mL). The organic phase was 
separated and washed with 10% HC1 (50 mL) and H 2 O (50 mL), dried and 
concentrated. The resulting oil was purified by column chrom atography 
(Alumina, 80-200 mesh, hexanerether = 1 :1 0 ) to give 5.77 g (43% from CR)-5) 
of a colorless oil.
!H NMR (100 MHz): 1.50 (s, 3 H, CH s-), 2.76 (d, 1 H, CH=oxirane, J app = 
5.3), 2.92 (d, 1 H, CH=oxirane, J app = 5.4), 5.59 (d, 1 H, C-CH=, J app = 16.3), 
6.60 (d, 1  H, =CH-CN, J app = 16.4). IR: 3060 (olefinic C-H stretch), 2226 
(CH=CH-C=N), 1634 (C=C stretch), 908 (olefinic C-H bend).
(J?) - 5 - (N, N  - Dim ethylam ino) - 4 - hydroxy - 4 - m ethyl - 2 - 
pentenenitrile (CR)-21). A solution of CR)-20 (52 mmol, 5.67 g) in  MeOH 
(14 mL) was added dropwise to a solution of HNMe2  (74 mmol, 3.34 g) in 
MeOH (20 mL). The reaction m ixture was stirred  for 1.5 h. Concentration of 
the reaction m ixture gave a light yellow oil. Vacuum distillation afforded 
7.10 g (89%) of a colorless oil.
!H NMR (100 MHz): 1.22 (s, 3 H, C tf 3 -C), 2.30 (s, 6  H, (CH 3 )2 N-), 2.45 (s, 2 
H, -CH2-), 5.78 (d, 1 H, C-CH=, J app = 16.0), 6.74 (d, 1 H, =CH-CN, J app = 
15.8). IR: 3464 (OH), 3060 (olefinic C-H stretch), 2225 (CH=CH-C=N), 1632 
(C=C stretch), 1042 (N-C).
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Compound (R)-10 (from CR)-21). A solution of 0R)-21 (5 mmol, 0.77 
g) in  absolute EtOH (20 mL) containing 10% Pd on charcoal (0.3 g) was 
hydrogenated a t 25 psi (pressure reaction apparatus) and r t  for 24 h. The 
reaction m ixture was filtered and concentrated affording a colorless oil, 
which was purified by column chrom atography (SiC>2 , 70-230 mesh, 
methanol) (0.68 g, 87%).
IR and *H NMR spectra are the same as compound 10.
(SM l-M ethyloxiranyl)m ethyl 4-nitrobenzenesulfonate (0S)-22).
A solution of 4-nitrobenzenesulfonyl chloride (19.4 mmol, 4.3 g) in  CH 2 CI2  
(10 mL) was slowly added to a stirred  m ixture of (R )-2 -methylglycidol (15.3 
mmol, 1.39 g, 97% purity) and E t 3 N (23.7 mmol, 2.37 g) in  CH 2 CI2  (10 mL) a t 
0 °C (ice-water bath). The reaction m ixture was stirred for additional 3 h  a t 
0 °C and then  stored in  freezer for 10-12 h. The reaction m ixture was diluted 
with cold CH 2 CI2  (10 mL) and filtered with suction to remove precipitated 
ammonium salt which then was washed w ith cold CH 2 CI2  (10 mL). The 
m other liquor was washed w ith cold 5% HC1 (10 mL), satd  NaHCC> 3  (10 mL), 
cold H 2 O ( 2 x 8  mL), and dried. Concentration of the solution gave 4.06 g of a 
light yellow solid. Recrystallization from EtOH gave 3.26 g (78 %) of (<S)-22. 
1H NMR (100 MHz): 1.37 (s, 3 H, CH r ), 2.67 (d, 1 H, H-CH=oxirane, J app = 
4.7), 2.72 (d, 1 H, H-CH=oxirane, J app = 4.7), 4.01 (d, 1 H, # -C H O S 0 2 Ar, 
Japp = 10.9), 4.27 (d, 1  H, H -CH O S0 2 Ar, J app = 10.9), 8.09-8.47 (m, 4 H, Bz).
CR)-2-Hydroxy-3-iodo-2-methylpropyl 4-nitrobenzenesulfonate  
((J?)-23). Compound (S)-22 (0.18 mmol, 50 mg) was added to a solution of
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N al (0.3 mmol, 45 mg) in  acetic acid (0.10 mL) and H 2 O (0.01 mL) a t 5 °C. 
After 1  h, the m ixture was poured into H 20  (3 mL). The aqueous solution 
was extracted with E t20  ( 3 x 2  mL). The combined E t20  extracts were 
washed with satd  NaHCC> 3  un til neu tral (a trace of NaHSC> 3  removed free 
I2), then w ith H 20  (3 mL), and dried. Concentration of the solution gave a 
light yellow solid. Crystals for X-ray analysis were obtained by 
recrystallization from MeOH.
*H NMR (100 Hz): 1.41 (s, 3 H, CH s-), 3.31 (s, 2 H, ICH2-), 4.11 (s, 2 H, CH2- 
OS), 8.10-8.49 (m, 4 H, Bz).
(2R, 6R; 2R, 6S; 2S, 6S; 2S, 6R) - 2 - (2 - Cyanoethyl) - 6 - 
(m ethoxyearbonyl)m ethyl-2,4,4-trim ethylm orpholinium  bromide (7). 
To a stirred solution of methyl-4-bromo-2-butenoate (14 mmol, 2.51 g) in  
CH 3 N 0 2  (30 mL) was added 10 (14 mmol, 2.18 g) dissolved in  CH 3 N 0 2  (20 
mL). The solution was stirred  a t 50-60 °C for 3 h. After cooling to rt, the 
reaction m ixture was concentrated and the residue was w ashed with E t2 0 . 
After drying under vacuum, it  was dissolved in  MeOH (130 mL) and refluxed 
for 18 h. Concentration of the reaction m ixture gave a brown oil, which was 
washed w ith ether and dried under vacuum  affording 4.70 g (100%) of a 
yellow oil, which was used for next reaction w ithout fu rther purification.
M ethyl (2S, 6R; 2R, 6S ) - 2 - [6 - (2 - cyanoethyl) - 4, 6 - dim ethyl 
m orpholinyl] acetate ((2S, 6R;2R, 6S )-8) and m ethyl {2R, 6R;2S, 6’S)-2-[6- 
(2-cyanoethyl)-4,6-dim ethylm orpholinyl]acetate ((2R, 6R; 2S, 6S)-8). 
Crude 7 (14 mmol, 4.70 g) was dissolved in  A^A/'-dimethylethanolamine (20
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mL) a t 50 °C under N 2 . After 15 min, thiophenol (42 mmol, 4.6 g) was added 
in one portion, and the tem perature was raised to 70 °C for 24 h. The 
reaction m ixture was then cooled to rt. The pH was adjusted to 1-2 with 10% 
HC1. The m ixture was extracted w ith hexanes (3 x 20 mL). To the aqueous 
layer, 10% NaOH was added until pH~12. The aqueous layer was extracted 
w ith CH 2 Cl2  (4 x 20 mL). The combined CH 2 CI2  extracts were washed with 
H 20  (2 x 20 mL) and dried. Concentration of the solution gave crude product 
8  as a  m ixture of four stereoisomers. Separation of this m ixture by column 
chromatography (SiC>2 , 230-400 mesh, EtOAcrMeOH = 100:3) gave a solid 
{(2R,6R;2S,6S)-8 , 0.36 g, m p 48.8-49.8 °C) and an  oil i(2S,6R; 2R,6S)-8 , 0.48 
g) (total yield: 25% from 10). Crystals of (2R,6R;2S,6S)-8 for X-ray analysis 
were obtained by crystallization from hexanes.
(2R,6R;2S,6S)-8 :
!H NMR (400 MHz): 1.10 (s, 3 H, CH 3 -C6 ), 1.50-1.58 (m, 1 H, H-CHCH 2 CN), 
1.67 (t, 1  H, H(ax)-C3, J app = 10.8), 1.82 (d, 1  H, H(ax)-C5, J app = 11.5), 2.21 
(s, 3 H, CH 3 -N), 2.32-2.52 (m, 4 H, CH 2 C 0 2 CH3, CH 2 CN), 2.47 (d, 1 H, 
H(eq)-C5, J app = 11.5), 2.68 (d, 1 H, H(eq)-C3, J app = 10.9), 2.83 (m, 1  H, H- 
CHCH 2 CN), 3.70 (s, 3 H, CH 3 -O), 4.03 (m, 1 H, H-C2). ^ C  NMR: 10.6 
(CH 2 CN), 24.6 (CH3 -C6 ), 29.6 (CH2 CH 2 CN), 38.5 (CH2 COO), 46.0 (CH3 -N),
51.7 (CH 3 -O), 59.1 (C3), 63.9 (C5), 66.3 (C2 ), 72.4 (C6 ), 120.6 (CN), 171.2 
(C=O). IR: 2246 (C=N), 1739 (C=0). MS m /e  (relative intensity): 240 (11.6), 
225 (0.5), 209 (24.0), 200 (1.1), 186 (4.9), 181 (1.1), 167 (9.1), 143 (42.7), 128 
(20.8), 115 (7.0), 98 (24.1), 84 (98.2), 82 (9.4), 70 (46.7), 59 (19.9), 57 (21.1), 43
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(100), 42 (68.2), 41 (29.2), 29 (6.5). Anal. Calcd for C 1 2 H 2 oN2 0 3 : C, 59.98; H, 
8.39; N, 11.66. Found: C, 59.79; H, 8.26; N, 11.44.
(2S,6R;2R,6S)-S:
!H NMR (400 MHz): 1.34 (s, 3 H, 6 -C # 3), 1.64 (t, 1 H, H(ax)-C3, J app = 1 0 .8 ), 
1.78 (m, 3 H, H(ax)-C5, C if2 CH 2 CN), 2.22 (s, 3 H, CH 3 -N), 2.32-2.48 (m, 5 H, 
H(eq)-C5, CH 2 C 0 2 CH3, CH 2 CN), 2.75 (d, 1 H, H(eq)-C3, J app = 10.9), 3.69 (s, 
3 H, C # 3 -0), 4.18 (m, 1 H, H-C2). NMR: 11.0 (CH 2 CN), 20.3 (CH3 -C6 ),
36.7 (CH 2 CH 2 CN), 38.9 (CH 2 COO), 46.3 (CH 3 -N), 51.7 (CH 3 -0), 59.9 (C3), 
62.9 (C5), 6 6 . 6  (C2), 72.2 (C6 ), 120.4 (CN), 171.2 (C=0). IR: 2248 (C=N), 
1739 (C=0). MS m /e  (relative intensity): 240 (10.4), 225 (0.7), 209 (23.1), 
200 (1.1), 186 (3.6), 181 (1.1), 167 (5.5), 143 (36.9), 128 (17.9), 115 (6.0), 98 
(25.0), 84 (97.5), 82 (8 .6 ), 70 (37.5), 59 (17.9), 57 (17.6), 43 (100), 42 (59.2), 41 
(26.6), 29 (5.6). Anal. Calcd for C 1 2 H 2 0 N 2 O3: C, 59.98; H, 8.39; N, 1 1 .6 6 . 
Found: C, 59.17; H, 8.73; N, 11.08.
D e te rm in a tio n  o f o p tic a l p u r i ty  o f 2 -m e th y lg ly c id o l by  
NMR. CR)-(+)-MTPA (2.05 g), S0C12  (4 mL) and NaCl (0.03 g) were refluxed 
for 50 h. The excess S0C12  was removed by vacuum evaporation and the 
residue was distilled to give CR)-(+)-MTPA-Cl. 8 2
To a solution of 2-methylglycidol (0.15 mmol, 13.2 mg) and  E t3N (0.06 
mL) in  CH 2 C12  (1 mL) was added (i?)-(+)-MTPA-Cl (0.10 mL). After being 
allowed to stand  in  refrigerator (0 °C) for 10 h, the reaction m ixture was 
washed w ith 5% H 2 SC> 4  (2 mL), filtered, and concentrated affording the 
Mosher's ester.
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1H NMR (200 MHz):
(a) Mosher's ester of (R)-(+)-2-methylglycidol: 1.36 (s, 3 H, C-CH3 ), 
2.64 (d, 1 H, H-CH=oxirane, J app = 4.6), 2.77 (d, 1  H, H-CH=oxirane, J app = 
4.6), 3.56 (s, 3 H, OCH3), 4.23 (d, 1 H, ff-CHO-MTPA, J app = 11.9), 4.47 (d, 1  
H, H-CHO-MTPA, J app = 11.8), 7.35-7.68 (m, 5 H, aromatic).
(b) Mosher's ester of (<S)-(-)-2-methylglycidol: 1.33 (s, 3 H, C-CH 3 ), 2.64 
(d, 1 H, H-CH=oxirane, J app = 4.7), 2.74 (d, 1 H, H-CH=oxirane, J app = 4.7), 
3.56 (s, 3 H, OCH 3 ), 4.16 (d, 1 H, H-CHO-MTPA, J app = 11.8), 4.50 (d, 1 H, 
H-CHO-MTPA, J app = 11.9), 7.35-7.68 (m, 5 H, aromatic).
The optical purities of (R )- and (S)-2-methylglycidols were determ ined 
by integration of the signals (dd) of -i^CO-W -M TPA. The ee values are 
88.4% for (R )-2-methylglycidol and 91.8% for (S)-2-methylglycidol.
D e te rm in a tio n  o f o p tic a l  p u r i ty  o f  c o m p o u n d  13 b y  *H NM R. A 
solution of 13 (3 mmol, 0.711 g) in  MeOH (9 mL) was added to a solution of 
HNMe2  ( 1 2  mmol, 0.54 g) in  MeOH (3 mL). The reaction m ixture was stirred 
for 2 h  and then  concentrated. MeOH (3 mL) was added, and  the precipitate 
was removed by filtration. The solution was concentrated. Again, MeOH (2 
mL) was added, and the precipitate was removed by filtration. The solution 
was placed in freezer for 0.5 h. The liquid was pipetted out and concentrated 
by ro tary  evaporation and then  placed under vacuum. Vacuum distillation of 
the residue gave 0.30 g (75%) of 3-dimethylamino-2-methylpropane-l,2-diol, 
6 , as a  colorless oil (bp: 150 °C/17 Torr). ^H NMR (200 MHz): 1.07 (s, 3 H, 
CH 3 -C), 2.37 (s, 6  H, CH 3 -N), 2.43 (dd, 1 H, H-CHN, J app = 13.7, 1.8), 2.57
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(d, 1 H, H-CHN, J app = 13.6), 3.46 (dd, 1 H, H-CHOH, J app = 11.0, 1.7), 3.67 
(d, 1 H, H-CHOH, J app = 1 1 .1 ). 13C NMR: 23.7 (CH 3 -C), 47.9 (CH 3 -N), 67.9 
(-CH2 -N), 70.7 (-CH2 -OH), 71.2 (C-OH). IR: 3405 (OH), 1044 (C-N). MS, 
FAB, m/e: 134 (M+ + 1). Anal. Calcd for C6 H 1 5 N 0 2: C, 54.14; H, 11.28; N, 
10.53. Found: C, 53.82; H, 11.10; N, 10.41.
To a  solution of 6  (0.18 mmol, 24 mg) and E t3N (0.05 mL) in CH 2 C12  (1 
mL) was added CR)-(+)-MTPA-Cl (0.10 mL) a t 0 °C. The reaction m ixture was 
placed in  a  freezer for 10 h. NaOH solution (5%) was added until pH ~ 1 2 . 
The phases were separated and the aqueous solution was extracted with 
CH 2 C12  ( 3 x 2  mL). The combined CH 2 C12  extracts were w ashed w ith H 20  (2 
x 5 mL), dried, and concentrated to give M osher’s ester, 15, as an  oil.
The optical purities of (R )- and (SO-13 were determ ined by integration 
of the *H NMR signals of CH3-C of Mosher's ester, 15. For optical enriched 
13, the m inor isomer was undetectable.
!H NMR (400 MHz): 1.086 (s, CH 3 -C) for M osher’s ester of (S)-6 , 1.069 (s, 
CH 3 -C) for Mosher's ester of (R)-6 .
C h a p t e r  III
INHIBITION OF CAT BY FOUR STEREOISOMERS 
OF 6-CARBOXYLATOMETHYL-2- 
HYDROXYMETHYL-2,4,4-TRIMETHYL 
MORPHOLINIUM
The four stereoisomers of 6-carboxylatomethyl-2-hydroxymethyl-2,4,4- 
trim ethylm orpholinium , II, were tested as specific inhibitors of CAT by Drs. 
Noirfn Nic a' Bhaird and Rona R. Ramsay a t UCSF. The resu lts are 
presented and discussed in th is chapter.
III .l. PREVIOUS WORK
Pigeon breast CAT indiscrim inately binds both enantiom ers of 
carnitine and acetylcarnitine , 1 0 3 >1 0 4  which indicates a two-point recognition 
of carnitine, involving carboxylate and trim ethylam m onium  groups. Cff)- 
C arnitine and (R )-acetylcarnitine are substrates in  the forward and  reverse 
reactions respectively, while the S  enantiom ers are competitive 
inhibitors. 103,104 This stereospecificity indicates th a t the location of the CoA 
binding site m ust be closer to the hydroxyl on (R)-carnitine th an  the one on 
(S)-carnitine. (Figure I I I . l ) . 7 2
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Based on the hypothesis for the mode of substrate recognition in  CAT, 
a mechanism  for the reversible acetyl transfer between carnitine and CoA 
has been proposed (Scheme I II .I ) . 7 2  In th is mechanism, the thiolate attacks 
on the Re face of the ester forming R  configuration on the tetrahedral 
interm ediate carbon.
K{ (|HM)
24. R = CH2C 0 2H 530
25. R = CH3 (racemic) 1080
26. R = H (racemic) 1000
F ig u re  III.2. T etrahedral interm ediate analogues and 
their A- values w ith respect to CR)-carnitine
Three tetrahedral-in term ediate analogues , 1 0 5  synthesized and assayed 
w ith CAT in  1987, (Figure III.2) m ust have the same configuration a t C6  as 
(-R)-carnitine does a t C3 to effectively inhibit CAT. Of these analogues, 24 
binds m ost strongly, w ith a K\ h a lf  th a t of the racemic compounds 25 and 26. 
Because every molecule of 24 has one side th a t correctly matches the 
configuration of (jR)-carnitine and only h a lf of the molecules of racemic 25 
and 26 have the correct configuration of (i?)-carnitine, the twofold 
im provem ent in  binding for 24 suggests th a t CAT is selectively binding one 
configuration of these inhibitors more tightly than  the others (chiral 
recognition of C6 ). To confirm this speculation, more direct and potent
82
evidence is needed. In  addition, those analogues do not te s t the configuration 
of the te trahedral interm ediate carbon (C2 in  the analogues) because 24 is a 
meso (R S ), 25 is a  (R S\SR ) racem ate, and 26 is a (R;S) racem ate. Inhibition 
studies w ith the four stereoisomers of I I  provide a te s t of the configuration 
stereocenters.
III.2. RESU LTS AND D ISCU SSIO N
The concentrations of the inhibitors needed for 50% inhibition (IC5 0 ) of 
commercial pigeon breast CAT have been determ ined a t 250 p.M of (R )- 
acetylcarnitine (Km = 350 |iM). The data  are shown in  Table III.l. All the 
four stereoisomers of I I  inhib it CAT to varying degrees. Compound (2S,6R)- 
II is the most potent inhibitor of CAT among these four stereoisomers. The 
value of K\ for th is stereoisomer shows th a t it binds 2-fold better th an  (R)- 
acetylcarnitine to CAT. The da ta  in  Table III .l also indicate th a t CAT 
recognizes both the configurations of C6  and C2 in  the tetrahedral- 
interm ediate analogues.
Compound (2S,6R)-II binds 10-fold better th an  (2S,6S)-II to CAT. 
Both of them  have the same configuration of C2. Compounds (2R,6R)-II 
binds 2.5-fold better than  C2f?,6S)-II to CAT. Both of them  also have the 
same configuration of C2. The difference in  both comparisons of inhibition of 
CAT is the difference of configurations of carnitine fragm ents (C6 ). These 
comparisons confirm the previous conclusion th a t CAT recognizes the 
configuration of C6  and strongly prefers R  configuration.
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T ab le  I I I .l .  Inhibition of 6 -carboxylatomethyl-2 -hydroxymethyl- 
2,4,4-trimethylmorpholinium on CAT
Inhibitor Structure IC 50 ( m M )  A'j ( g M )
(2S, 6R)-Yl
O H
,Me
M e  M e
0.42 187
(2R,  6R)-n
O H
.Me
M e  M e
1.36
(.2R, 6S)-1l
'OoC
H
,O H
Me
M e  M e
3.41
(2S, 6S)-II
' 0 0C
H
/
^,OH 
0^1 Ale
I
; Nv
M e  M e
4.04
Pigeon breast CAT binds enantiom ers of both carnitine and 
acetylcarnitine equally well . 1 0 3 ’ 1 0 4  But only (R)-enantiomers can undergo 
acetyl transfer, which m eans th a t only CR)-enantiomers can form a 
tetrahedral-interm ediate. W hen the tetrahedral-in term ediate forms (acetyl-
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CoA is attached to carnitine), the enzyme is probably in  a different 
conformation th an  when it binds carnitine or acetylcarnitine. This enzymic 
conformation complements only the CR)-carnitine tetrahedral-interm ediate. 
Therefore, the enzyme in  th is conformation should be inhibited by the 
reaction-interm ediate analogues th a t have the same configuration as (R)- 
carnitine (C6 ). This speculation agrees w ith our results, confirming the 
hypothesis th a t the enzymic conformation for binding these analogues is 
different th an  the enzymic conformation th a t binds the substrates.
Compounds (2S,6R)-II and (2R,6R)-II have the same configuration on 
C6  bu t different configurations on C2 . Compound (2S,6R)-II binds 3-fold 
better th an  (2R,6R)-II to CAT, suggesting th a t S  configuration of C2 is 
required for enzyme recognition. This resu lt strongly supports the 
mechanism for acetyl transfer between carnitine and  CoA proposed by 
Gandour e t al? 2  (Scheme III.l). The idea is th a t the thiolate approaches the 
acyloxy from the less-congested side and attacks on the Re face of the ester to 
form R  configuration on the tetrahedral-in term ediate (C5). The S  
configuration in  the analogue inhibitor (C2) is the same relative 
configuration as the R  configuration for the tetrahedral-in term ediate (C5). 
This idea agrees w ith the observation th a t C2»S,6R)-II is the best inhibitor 
among four stereoisomers.
Compared w ith the previously synthesized analogue inhibitors 24, 25, 
and 26, which are meso and  racemic compounds and do not test the 
configuration of te trahedral interm ediate carbon (C2 in  the analogues), our
analogues are chiral compounds so th a t they can test not only the 
configuration of carnitine fragm ent bu t also the configuration of te trahedral 
interm ediate carbon. Compounds C2£,6i?)-II, 24, and  the more active 
enantiom ers of 25 and 26 have the same configuration on C6 . Racemic 25 
and 26 have K\ values of 1080 and 1000 respectively. We assum e th a t the 
more active enantiom ers of 25 and 26 have K j values of 540 and 500 
respectively. Compound (2S,6R)-II binds nearly 3-fold better th an  24 and 
the active enantiom ers of 25 and 26 to CAT. The possible reasons for these 
results are th a t (1) the configuration of C2 in  (2S,6R)-Il fits the enzyme 
much better th an  the configurations of C2 in 24, 25, and 26 do, and (2) 
hydrogen bonding is im portant for (2,S,6R)-II.
By comparing the IC 5 0  values of (2S,,6i?)-II w ith (2R,6R)-II and 
(2S,6R)-11 w ith (2S,6S)-II, we can see th a t the configuration of C6  is more 
crucial than  th a t of C2 . We speculate th a t C6  in  the analogue mimics C3 in 
the tetrahedral-in term ediate better than  C2  in  the analogue mimics C5 in 
the interm ediate (Scheme III.l). Carbon 6  in  the analogue and C3 in  the 
interm ediate have almost the same environment, while in  the interm ediate 
C5 is connected to CoA and a  negatively charged oxygen and in  the analogue 
C2 is in  a six-membered ring and connected to a hydroxymethyl group. This 
difference m ight affect enzyme recognition. In addition, the binding of CoA 
to CAT is different from the interaction of hydroxymethyl w ith CAT. 
Therefore, the im portance of the configuration of C5 in  the tetrahedral- 
interm ediate m ight be underestim ated by th is inhibitory study.
III-3. CO N CLUSIO N
In conclusion, the results of the study verify firmly th a t the enzyme 
recognizes both configurations of C2 and C6  in  the tetrahedral-interm ediate 
analogues. If the enzyme hinds these analogue inhibitors as it binds the 
tetrahedral-interm ediate, we can conclude th a t the enzymic conformation for 
binding the substrates is different from the enzymic conformation th a t binds 
the tetrahedral-interm ediate. CAT binds both R  and S  enantiom ers of 
carnitine or acetylcarnitine bu t the chiral center of carnitine is not 
recognized. The chiral recognition of carnitine is caused by the binding of 
CoA. The thiolate of CoA attacks on the Re face of the ester of carnitine to 
form R  configuration on the te trahedral interm ediate carbon. Only the 
tetrahedral-in term ediate w ith R  configurations on C3 and C5 forms in  the 
acetyl transfer reaction between carnitine and CoA. Therefore, only (R)- 
enantiom ers can undergo acetyl transfer.
C h a p t e r  IV
CONCLUSION
IV. 1. RESU LTS
We have developed new synthetic methods and added new members to 
the family of tetrahedral-reaction-interm ediate analogue inhibitors. The 
inhibitory effects of these new analogues on CAT have been studied.
1. We have prepared four stereoisomers of 6 -carboxylatomethyl-2 - 
hydroxymethyl-2, 4, 4-trim ethyl morpholinium, II, which are reaction- 
interm ediate analogue inhibitors and will serve as precursors to four 
stereoisomers of 2-(3-aminopropyl)-6-carboxylatomethyl-2,4,4-trim ethyl 
morpholinium, III, and the ta rge t molecules of the project. This is the first 
tim e th a t four stereoisomers of th is type of acyltransferase inhibitors are 
made.
2 . We have prepared methyl (2S,6S;2R,6R)- and (2S,6R',2R,6S)-2-[6- 
(2-cyanoethyl)-4,6-dimethylmorpholinyl]acetate, 8 , which are precursors to 
molecules III.
3. We have resolved racemic m ixture of 5-(N,N-dimethylamino)-4- 
hydroxy-4-m ethylpentanenitrile, 10, which makes it  possible th a t four
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stereoisomers of 2-(3-aminopropyl)-6-carboxylatomethyl-2,4,4-trim ethyl 
morpholinium, III, be made starting  w ith nonchiral compound, 3-methyl-3- 
buten-l-ol.
4. The four stereoisomers of I I  have been tested as specific inhibitors 
of CAT. The results confirm the hypothesis for the mode of substrate 
recognition in  CAT and the m echanism for acetyl transfer between carnitine 
and CoA.
Although I did not get 2-(3-aminopropyl)-6-carboxylatomethyl-2,4,4- 
trim ethylmorpholinium, III, due to various reasons, I came relatively close 
by preparing four stereoisomers of 6-carboxylatomethyl-2-hydroymethyl-2, 4, 
4-trim ethyl morpholinium, II, which are precursors to III, and resolving 
racemic m ixture of 5-(Ar,A’-dimethylamino)-4-hydroxy-4-
m ethylpentanenitrile, 1 0 , which m akes it  possible th a t four stereoisomers of 
I II  be made starting  w ith nonchiral compound, 3-methyl-3-buten-l-ol. 
Furtherm ore, compound II  can lead to other compounds th a t m ight be potent 
inhibitors, (see below)
IV.2. FU TU RE D IR E C TIO N
The future work will be directed toward the synthesis of four 
stereoisomers of 2-(3-aminopropyl)-6-carboxylatomethyl-2,4,4-trim ethyl
morpholinium, III, which are precursors to the target molecules of the 
project.
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According to the results of our work (section IV. 1), there are a num ber 
of possible synthetic routes for III, which are shown in  Scheme IV. 1  and 
Scheme IV. 2.
Scheme IV. 1 is a continuation of Scheme 11.15. Methyl 2-[6-(2- 
eyanoethyl)-4,6-dimethylmorpholinyl]acetate, 8 , can be converted into 
compound III  by m ethylation of te rtia ry  am ine, hydrolysis of methyl ester, 
and reduction of cyano group. The sequence of those th ree  reactions m ight be 
crucial to th is conversion. I t  is not difficult to find out the correct sequence. 
Four stereoisomers of 8  can be made from 3-m ethyl-3-buten-l-ol and optical 
resolution of (RS)-5-(A^,A’-dimethylamino)-4-hydroxy-4-methylpentanenitrile, 
10, is needed.
COOM e C O O M e
COO
S ch em e IV. 1
In Scheme IV.2, compound I I I  can be made in  a  num ber of ways. In 
these synthetic routes, three more analogue inhibitors, 27, 30, and 33, can be 
made in  addition to III. In synthetic route of Scheme IV. 1, only one more 
analogue inhibitor, 27, can be made in  addition to III. Furtherm ore, 
compounds 1, 2, and II  in  Scheme IV.2 are made starting  w ith chiral 
compound (R )- or (S)-2-methylglycidol (Scheme II.6 ), no optical resolution is 
needed. Therefore, Scheme IV.2 will be better th an  Scheme IV. 1.
COOM e OH
(2R, 6S)-2
COOM e O
COOMe
COOMe
COOM e OH
(.2R,  65) - !
COOMe
NaOH
h 2o  ‘
.CN
COOMe
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A p p e n d ix  A
CRYSTALLOGRAPHIC DATA FOR 
( 2 S , 6 R ) -2 -HYDROXYMETH YL-6- 
(METHOXY CARBONYL)METHYL-2,4,4- 
TRIMETHYLMORPHOLINIUM IODIDE
C 1 1 H 2 2 NO 4 I, Mr = 359.2, orthorhombic, P 2]2]2 i, a = 9.5519(6), 6 = 
12.4000(6), c = 25.723(2) A, V=  3046.7(6) A3, Z  = 8, Dx = 1.564 g cm’3 a t 293 
K, X (Mo Ka  ) =  0.71073 A, |li =  2 0 . 8  cm '1, F(0 0 0 ) =  1440, 6251 unique data 
measured, final R  = 0.027 for 5230 reflections w ith I > 3o(I). Two 
independent formula units in  asymmetric unit.
Table A .l. Coordinates and isotropic therm al param eters
Ba] = (8 tt7 3 ) 1 1 ^ ;
> 1 >ai a <a j
Atom X y z B eq (A2)
1 1 0.23568(3) 0.21429(2) 0.59731(1) 3.927(5)
1 2 0.68574(3) 0 .2 1 2 1 1 (2 ) 0.08180(1) 4.820(6)
OlA 0.2750(3) 0.2618(2) 0.17058(9) 3.03(5)
02A 0.4204(3) -0.0606(2) 0.2416(1) 5.49(8)
03A 0.1908(3) -0.0369(2) 0.2450(1) 5.71(8)
04A -0.0145(3) 0.3600(2) 0.0912(1) 4.07(6)
N1A 0.2419(3) 0.1345(2) 0.0766(1) 2.73(5)
CIA 0.3112(4) 0.0927(3) 0.1253(1) 2.91(7)
C2A 0.2556(4) 0.1479(2) 0.1737(1) 2.80(6)
(Table con'd.)
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Atom X y z B eq (A2)
C3A 0.2125(4) 0.3136(2) 0.1262(1) 2.99(7)
C4A 0.2537(4) 0.2561(2) 0.0762(1) 2.87(6)
C5A 0.3191(5) 0.0904(3) 0.0308(2) 3.84(8)
C6 A 0.0934(4) 0.0964(3) 0.0720(2) 3.54(8)
C7A 0.3391(4) 0.1103(3) 0.2205(2) 3.51(8)
C8 A 0.3057(4) -0.0029(3) 0.2361(2) 3.53(8)
C9A 0.2765(5) 0.4251(3) 0.1238(2) 4.45(9)
C 1 0 A 0.0553(4) 0.3232(3) 0.1366(2) 3.49(8)
C 1 1 A 0.4029(7) -0.1699(4) 0.2595(3) 8.9(2)
01B 0.2585(3) 0.2319(2) 0.33758(9) 3.65(5)
02B 0.1613(4) 0.5479(2) 0.2442(1) 4.86(7)
03B 0.0742(3) 0.5376(2) 0.3243(1) 4.03(6)
04B 0.0916(3) 0.0669(2) 0.4380(1) 4.10(6)
N IB 0.2739(3) 0.3398(2) 0.4377(10 2.83(6)
C1B 0.2860(4) 0.3949(3) 0.3857(1) 3.29(7)
C2B 0.2037(4) 0.3378(3) 0.3446(1) 3.13(7)
C3B 0.2533(4) 0.1651(3) 0.3836(1) 3.29(7)
C4B 0.3165(4) 0.2234(3) 0.4305(1) 3.13(7)
C5B 0.3756(5) 0.3914(3) 0.4750(2) 3.95(8)
C6 B 0.1320(4) 0.3520(3) 0.4601(2) 3.56(8)
C7B 0.2186(5) 0.3948(3) 0.2922(1) 4.10(9)
C8 B 0.1427(4) 0.5001(3) 0.2906(1) 3.24(8)
C9B 0.3507(6) 0.0704(3) 0.3724(2) 5.1(1)
C10B 0.1047(5) 0.1247(3) 0.3906(2) 3.72(8)
C U B 0.0913(6) 0.6495(3) 0.2366(2) 5.0(1)
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T ab le  A.2. Coordinates and isotropic therm al param eters
for hydrogen atoms
Atom x y z Bjso (A2)
H 40A -0.083(6) 0.322(4) 0.087(2) 1 0 (2 )
H lA a 0.4090 0.1051 0.1229 3
H lA b 0.2941 0.0174 0.1280 3
H2A 0.1589 0.1307 0.1766 3
H4Aa 0.1952 0.2825 0.0491 3
H4Ab 0.3483 0.2740 0.0688 3
H5Aa 0.4141 0.1128 0.0322 4
H5Ab 0.3148 0.0138 0.0313 4
H5Ac 0.2775 0.1164 -0.0003 4
H 6 Aa 0.0405 0.1228 0.1005 4
H 6 Ab 0.0541 0.1223 0.0404 4
H 6 Ac 0.0914 0.0197 0.0721 4
H7Aa 0.3191 0.1567 0.2489 4
H7Ab 0.4359 0.1145 0 . 2 1 2 2 4
H9Aa 0.3741 0.4191 0.1173 5
H9Ab 0.2338 0.4649 0.0965 5
H9Ac 0.2618 0.4610 0.1559 5
HlOAa 0.0192 0.2545 0.1461 4
HlOAa 0.0400 0.3729 0.1641 4
H llA a 0.4916 -0.1992 0.2682 1 1
H llA b 0.3613 -0.2119 0.2327 1 1
H llA c 0.3441 -0.1705 0.2892 1 1
H 40B 0.063(3) 0.007(2) 0.430(1) 1.9(6)
H IB a 0.3817 0.3964 0.3756 4
H IBb 0.2520 0.4666 0.3887 4
H2B 0.1085 0.3367 0.3553 4
H4Ba 0.2896 0.1849 0.4608 4
H4Bb 0.4154 0.2213 0.4270 4
H5Ba 0.4679 0.3848 0.4617 5
(T ab le  con'd.)
106
Atom x y z Biso (A2)
H5Bb 0.3528 0.4655 0.4790 5
H5Bc 0.3698 0.3562 0.5077 5
H 6 Ba 0.0652 0.3201 0.4373 4
H 6 Bb 0.1282 0.3172 0.4929 4
H 6 Bc 0.1113 0.4264 0.4642 4
H7Ba 0.1819 0.3492 0.2658 5
H7Bb 0.3151 0.4076 0.2858 5
H9Ba 0.4436 0.0961 0.3680 6
H9Bb 0.3478 0 . 0 2 1 1 0.4006 6
H9Bc 0.3212 0.0349 0.3415 6
HlOBa 0.0424 0.1844 0.3910 4
HlOBb 0.0813 0.0783 0.3625 4
H llB a 0.1191 0.6797 0.2043 6
H llB b 0.1155 0.6974 0.2640 6
H llB c -0.0071 0.6383 0.2365 6
A p p e n d ix  B
CRYSTALLOGRAPHIC DATA FOR 
(2R,6R)-2-HYDROXYMETHYL-6- 
(METHOXY CARBONYL)METHYL-2,4,4- 
TRIMETHYLMORPHOLINIUM IODIDE
C 1 1 H 2 2 NO 4 I, Mr = 359.2, orthorhombic, P2^2^2-\_, a = 7.9611(4), b = 
13.6603(5), c = 14.0588(9) A, V = 1528.9(2) A3, Z  = 4, Dx = 1.561 g c n r3 a t 291 
K, X (Mo K a  ) = 0.71073 A, |u. = 20.7 cm-1, 1 (^0 0 0 ) = 720, 6685 unique data 
m easured, final R  = 0.038 for 4863 reflections w ith I > 3a(I).
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T ab le  B .l. Coordinates and isotropic therm al param eters
' j
Atom X y z B eq (A2)
I 0.72283(3) 0.19805(2) 0.31553(2) 4.409(4)
01 0.3997(3) 0.3314(2) 0.1367(2) 3.02(4)
02 0.7953(4) 0.5316(2) 0.0871(2) 4.66(5)
03 0.5515(4) 0.5008(2) 0.0135(2) 4.56(6)
0 4 0.3931(5) 0.1299(2) 0.1514(2) 5.14(7)
N 0.1985(3) 0.3646(2) 0.3058(2) 3.11(5)
C l 0.3680(4) 0.4099(2) 0.2904(2) 2.87(5)
C2 0.4101(4) 0.4228(2) 0.1850(2) 2.81(4)
C3 0.2380(4) 0.2864(2) 0.1415(2) 3.51(6)
C4 0.1844(5) 0.2738(2) 0.2448(3) 3.62(6)
C5 0.1853(6) 0.3332(3) 0.4074(3) 4.36(7)
C6 0.0603(5) 0.4365(3) 0.2885(3) 4.60(8)
C7 0.5891(4) 0.4576(2) 0.1780(2) 3.10(5)
C8 0.6372(5) 0.4982(2) 0.0828(3) 3.32(6)
C9 0.1120(6) 0.3362(4) 0.0771(3) 5.7(1)
CIO 0.2695(6) 0.1829(3) 0.1018(3) 4.56(7)
C l l 0.8611(7) 0.5730(3) 0.0005(3) 5.87(9)
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T a b le  B.2. Coordinates and isotropic therm al param eters
for hydrogen atoms
Atom X y z Biso (A2)
H 40 0.465(9) 0.169(4) 0.186(5) 11(2)
H la 0.4506 0.3689 0.3168 3
H lb 0.3699 0.4722 0.3202 3
H2 0.3335 0.4678 0.1573 3
H4a 0.0704 0.2531 0.2453 4
H4b 0.2528 0.2243 0.2723 4
H5a 0.2715 0.2872 0.4211 5
H5b 0.1972 0.3886 0.4476 5
H5c 0.0788 0.3038 0.4179 5
H 6a 0.0645 0.4582 0.2243 5
H6b -0.0449 0.4061 0.3002 5
H6c 0.0734 0.4909 0.3298 5
H7a 0.6609 0.4038 0.1916 4
H7b 0.6054 0.5074 0.2242 4
H9a 0.1567 0.3405 0.0146 7
H9b 0.0109 0.2992 0.0758 7
H9c 0.0891 0.4001 0.1004 7
HlOa 0.1671 0.1473 0.1047 5
HlOb 0.3039 0.1888 0.0373 5
H l l a 0.9784 0.5826 0.0058 7
H l l b 0.8080 0.6341 -0.0112 7
H l l c 0.8390 0.5297 -0.0509 7
A p p e n d ix  C
CRYSTALLOGRAPHIC DATA FOR 
(2R,6S)-6-CARBOXYLATOMETHYL- 
2-HYDROXYMETHYL-2,4,4- 
TRIMETHYLMORPHOLINIUM
CioH i9N 0 4.2H 20 , Mr = 253.3, monoclinic, P2h a = 7.8558(6), b = 9.8998(7), 
c = 8.6266(5) A, P = 101.314(5)°, V = 657.9(2) A3, Z = 2, Dx = 1.278 g cm '3 a t 
294 K, X (Cu Ka  ) = 1.54184 A, |i = 8.45 cm '1, F(000) = 276, 2641 unique 
data m easured, final R = 0.0369 for 2571 reflections w ith I > 3a(I).
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I l l
T ab le  C .l. Coordinates and isotropic therm al param eters
=(8jr2/ 3 ) i ; i U ija;a;alaj
'  J
Atom X y z Beq (A2)
0 1 0.5734(1) 0 0.7318(1) 2.99(2)
0 2 0.2195(2) -0.2240(2) 0.5232(2) 4.03(3)
0 3 0.4153(2) -0.3195(2) 0.7085(2) 4.48(3)
0 4 0.7828(2) 0.0209(2) 1.1530(1) 4.10(3)
N 0.9454(2) -0.0086(2) 0.7484(2) 2.86(2)
C l 0.8128(2) -0.0613(2) 0.6105(2) 2.90(3)
C2 0.6536(2) -0.1108(2) 0.6667(2) 2.79(3)
C3 0.6790(2) 0.0589(2) 0.8696(2) 2.70(3)
C4 0.8600(2) 0.0943(2) 0.8384(2) 2.98(3)
C5 1.0877(2) 0.0633(2) 0.6876(2) 4.11(4)
C6 1.0276(2) -0.1237(2) 0.8512(2) 3.71(3)
C7 0.5177(2) -0.1685(2) 0.5331(2) 3.24(3)
C8 0.3719(2) -0.2420(2) 0.5931(2) 2.92(3)
C9 0.5914(2) 0.1921(2) 0.8928(2) 3.26(3)
CIO 0.6772(2) -0.0322(2) 1.0131(2) 3.21(3)
01W 0.2699(2) 0.1030(2) 0.0995(2) 4.77(3)
02W 0.1097(2) -0.0590(3) 0.2768(2) 9.42(5)
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T a b le  C.2. Coordinates and isotropic therm al param eters
for hydrogen atoms
Atom X y z B iso (A2)
H 40 0.713(4) 0.047(5) 1.218(4) 10(1)
H la 0.875(2) -0.133(2) 0.564(2) 3.1(4)
H lb 0.785(2) 0.018(2) 0.535(2) 3.1(4)
H2 0.687(2) -0.179(2) 0.749(2) 2.6(3)
H4a 0.838(3) 0.170(2) 0.762(3) 4.3(5)
H4b 0.944(2) 0.104(2) 0.940(2) 3.1(4)
H5a 1.025(3) 0.132(3) 0.618(3) 5.8(6)
H5b 1.168(3) 0.095(2) 0.777(3) 4.5(5)
H5c 1.143(3) -0.013(3) 0.626(3) 5.5(5)
H6a 0.932(2) -0.183(2) 0.891(2) 3.7(4)
H6b 1.086(3) -0.174(3) 0.786(3) 6.4(7)
H6c 1.109(3) -0.084(3) 0.933(3) 5.4(5)
H7a 0.576(3) -0.230(3) 0.482(3) 5.6(6)
H7b 0.471(3) -0.104(2) 0.458(2) 4.2(5)
H9a 0.594(3) 0.259(3) 0.804(3) 5.7(6)
H9b 0.471(3) 0.177(3) 0.892(3) 4.9(5)
H9c 0.656(3) 0.227(3) 0.997(3) 4.8(5)
HlOa 0.554(2) -0.032(2) 1.030(2) 3.9(4)
HlOb 0.725(3) -0.125(2) 0.998(2) 3.5(4)
H1W1 0.373(3) 0.127(3) 0.159(3) 4.5(5)
H2W1 0.225(3) 0.052(3) 0.176(3) 5.5(6)
H1W2 0.139(5) -0.088(5) 0.374(4) 11(1)
H2W2 -0.008(4) -0.041(3) 0.244(3) 6.8(7)
A p p e n d ix  D
CRYSTALLOGRAPHIC DATA FOR 
(2R,6R)-6-CARBOXYLATOMETHYL- 
2-HYDROXYMETHYL-2,4,4- 
TRIMETHYLMORPHOLINIUM
C i0H i9NO4.2H 2O, Mr = 253.3, orthorhombic, a = 7.8402(7), b =
12.5209(6), c = 13.0286(7) A ,V =  1279.0(3) A3, Z  = 4, Dx = 1.316 g cm '3 a t 292 
K, X (Cu Ka ) = 1.54184 A, |i = 8.7 cm '1, F(000) = 552, 2597 unique data 
m easured, final R  = 0.0334 for 2435 reflections w ith I > 3a(I).
113
114
T ab le  D .l. Coordinates and isotropic therm al param eters
fit t l=(87C2/ 3 ) £ £ U iia ; a ; a , a i
‘ j
Atom X y z B eq (A2)
0 1 0.3308(1) 0.55093(7) 0.59485(7) 2.04(2)
0 2 0.1842(2) 0.7990(1) 0.77761(9) 4.10(2)
03 0.3618(2) 0.79070(9) 0.6447(1) 3.78(2)
0 4 0.6578(1) 0.46173(9) 0.62969(9) 3.35(2)
N 0.1162(2) 0.46807(9) 0.43284(9) 2.45(2)
C l 0.0530(2) 0.5417(1) 0.5158(1) 2.35(2)
C2 0.1918(2) 0.6138(1) 0.5571(1) 1.94(2)
C3 0.4099(2) 0.4834(1) 0.5193(1) 2.06(2)
C4 0.2752(2) 0.4118(1) 0.4696(1) 2.36(2)
C5 0.1424(2) 0.5273(1) 0.3338(1) 3.46(3)
C6 -0.0186(2) 0.3848(1) 0.4143(2) 4.03(3)
C7 0.1185(2) 0.6755(1) 0.6469(1) 2.18(2)
C 8 0.2329(2) 0.7618(1) 0.6923(1) 2.45(2)
C9 0.5197(2) 0.5478(1) 0.4445(1) 2.90(3)
CIO 0.5232(2) 0.4066(1) 0.5803(1) 2.45(2)
01W 0.6750(2) 0.6867(1) 0.6705(1) 4.46(3)
02W 0.8622(2) 0.7462(1) 0.8474(1) 5.35(3)
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T ab le  D.2. Coordinates and isotropic therm al param eters
for hydrogen atoms
Atom X y z Siso (A2)
H 40 0.705(4) 0.414(2) 0.659(2) 6 .0 (6 )
H la 0.014(2) 0.493(1) 0.571(1) 2.8(3))
H lb -0.042(2) 0.584(1) 0.485(1) 2.4(3)
H2 0.226(2) 0.660(1) 0.503(1) 2.3(3)
H4a 0.314(3) 0.374(1) 0.412(1) 3.3(4)
H4b 0.240(2) 0.357(1) 0.522(1) 2.9(3)
H5a 0.215(3) 0.587(2) 0.346(1) 4.2(4)
H5b 0.170(3) 0.475(2) 0.283(2) 4.9(5)
H5c 0.028(3) 0.555(2) 0.312(2) 6 .1 (6 )
H 6 a -0.038(3) 0.344(2) 0.487(1) 4.4(4)
H 6 b -0.115(3) 0.425(2) 0.389(2) 5.8(6)
H 6 c 0.023(3) 0.342(2) 0.360(2) 5.6(5)
H7a 0.092(2) 0.628(1) 0.700(1) 2.4(3)
H7b 0.016(2) 0.710(1) 0.624(1) 3.2(4)
H9a 0.615(3) 0.584(2) 0.476(2) 5.5(5)
H9b 0.557(3) 0.499(1) 0.394(2) 5.2(5)
H9c 0.455(3) 0.610(1) 0.405(1) 4.7(5)
HlOa 0.454(2) 0.367(1) 0.632(1) 3.0(4)
HlOb 0.561(3) 0.353(1) 0.535(1) 3.6(4)
H1W1 0.596(4) 0.723(2) 0.663(2) 6.9(7)
H2W1 0.677(4) 0.620(2) 0.659(2) 7.4(7)
H1W2 0.949(4) 0.781(2) 0.820(2) 6.3(6)
H2W2 0.820(4) 0.734(2) 0.791(2) 8.7(8)
A p p e n d ix  E
CRYSTALLOGRAPHIC DATA FOR 
METHYL ( 2 S , 6 S # R , 6 R ) - 2- 
[6-(2-CYANOETHYL)-4,6- 
DIMETHYLMORPHOLINYL]ACETATE
C 1 2 H 2 0 N 2 O3 , Mr = 240.3, triclinic, PI, a = 5.6057(4), b = 9.1737(7), c  = 
14.1151(10) A, a  = 74.430(7), p = 88.908(6), 7  = 79.302(6)°, V = 686.7(1) A3, Z 
= 2 , D x = 1.162 g cm ' 3  a t 297 K, X (Mo Ka  ) = 0.71073 A, |i = 0 . 8  cm '1, 
F(000) = 260.0, 2409 unique data m easured, final R = 0.040 for 1850 
reflections with I > 2a(I).
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T a b le  E .l .  Coordinates and isotropic therm al param eters
» j
Atom X y z B eq (A2)
0 1 0.1478(2) 0.3437(1) 0.77508(6) 3.84(2)
0 2 0.0572(2) 0.6770(1) 0.5993(1) 6.85(4)
03 0.4592(2) 0.6267(1) 0.59987(8) 5.33(3)
N1 -0.1319(3) 0.1366(1) 0.7412(1) 5.00(3)
N2 -0.6392(4) 0.7041(2) 0.8732(1) 8.44(5)
C l 0.0433(3) 0.1943(2) 0.6707(1) 4.97(4)
C2 0.0703(3) 0.3509(2) 0.6780(1) 3.82(3)
C3 -0.0015(3) 0.2750(2) 0.8525(1) 4.04(4)
C4 -0.0398(3) 0.1219(2) 0.8395(1) 5.19(4)
C5 -0.1843(4) -0.0096(2) 0.7321(2) 7.71(6)
C6 0.2589(3) 0.4188(2) 0.6118(1) 4.51(4)
C7 0.2421(3) 0.5856(2) 0.6039(1) 4.34(4)
C8 0.4578(4) 0.7879(2) 0.5869(2) 6.75(5)
C9 0.1474(4) 0.2508(2) 0.9463(1) 5.76(5)
CIO -0.2458(3) 0.3815(2) 0.8519(1) 4.33(4)
C l l -0.2261(3) 0.5475(2) 0.8417(1) 5.43(4)
C12 -0.4585(4) 0.6373(2) 0.8589(1) 5.78(5)
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T a b le  E.2. Coordinates and isotropic therm al param eters 
for hydrogen atoms
Atom X y z Biso (A2)
H la -0.007(3) 0.200(2) 0.606(1) 5.5(4)
H lb 0.201(3) 0.124(2) 0.683(1) 5.9(4)
H2 -0.087(2) 0.420(1) 0.6595(9) 4.2(3)
H4a 0.118(3) 0.046(2) 0.854(1) 6.6(4)
H4b -0.151(3) 0.081(2) 0.889(1) 6.5(4)
H5a -0.301(4) -0.046(2) 0.783(1) 10.2(6)
H5b -0.242(4) 0.006(2) 0.663(1) 10.3(6)
H5c -0.036(3) -0.093(2) 0.748(1) 8.9(5)
H6a 0.229(3) 0.414(2) 0.547(1) 5.4(4)
H6b 0.422(3) 0.361(2) 0.636(1) 5.9(4)
H8a 0.386(4) 0.819(2) 0.644(1) 10.3(6)
H8b 0.369(4) 0.855(2) 0.525(1) 10.8(6)
H8c 0.615(4) 0.802(2) 0.587(2) 11.3(6)
H9a 0.053(3) 0.214(2) 1.002(1) 7.7(5)
H9b 0.299(3) 0.173(2) 0.945(1) 7.9(5)
H9c 0.187(3) 0.354(2) 0.949(1) 7.9(5)
HlOa -0.322(3) 0.340(2) 0.913(1) 6.0(4)
HlOb -0.346(2) 0.381(1) 0.7991(9) 4.1(3)
H l l a -0.176(3) 0.597(2) 0.776(1) 8.7(5)
H I lb -0.118(3) 0.554(2) 0.890(1) 7.2(4)
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